US20220072288A1 - Medical treatment system and method of use - Google Patents
Medical treatment system and method of use Download PDFInfo
- Publication number
- US20220072288A1 US20220072288A1 US17/444,984 US202117444984A US2022072288A1 US 20220072288 A1 US20220072288 A1 US 20220072288A1 US 202117444984 A US202117444984 A US 202117444984A US 2022072288 A1 US2022072288 A1 US 2022072288A1
- Authority
- US
- United States
- Prior art keywords
- treatment
- oxygen
- chamber
- limb
- liner
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 148
- 238000000034 method Methods 0.000 title claims abstract description 23
- 239000003595 mist Substances 0.000 claims abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 72
- 239000003242 anti bacterial agent Substances 0.000 claims description 11
- 230000003115 biocidal effect Effects 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 94
- 239000001301 oxygen Substances 0.000 abstract description 93
- 229910052760 oxygen Inorganic materials 0.000 abstract description 93
- 239000007789 gas Substances 0.000 abstract description 23
- 239000003814 drug Substances 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 19
- 201000004384 Alopecia Diseases 0.000 abstract description 17
- 206010000496 acne Diseases 0.000 abstract description 14
- 230000003676 hair loss Effects 0.000 abstract description 13
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 11
- 208000024963 hair loss Diseases 0.000 abstract description 9
- 201000004647 tinea pedis Diseases 0.000 abstract description 7
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 abstract description 4
- 241000186427 Cutibacterium acnes Species 0.000 abstract description 4
- 206010017533 Fungal infection Diseases 0.000 abstract description 4
- 208000031888 Mycoses Diseases 0.000 abstract description 4
- 241000223238 Trichophyton Species 0.000 abstract description 4
- 208000025865 Ulcer Diseases 0.000 abstract description 4
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 4
- 229940055019 propionibacterium acne Drugs 0.000 abstract description 4
- 208000017520 skin disease Diseases 0.000 abstract description 4
- 208000001034 Frostbite Diseases 0.000 abstract description 3
- 231100000360 alopecia Toxicity 0.000 abstract description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract description 2
- 230000002538 fungal effect Effects 0.000 abstract description 2
- 230000003902 lesion Effects 0.000 abstract description 2
- 230000036269 ulceration Effects 0.000 abstract description 2
- 229910001882 dioxygen Inorganic materials 0.000 abstract 1
- 210000003414 extremity Anatomy 0.000 description 56
- 206010052428 Wound Diseases 0.000 description 50
- 208000027418 Wounds and injury Diseases 0.000 description 48
- 230000006870 function Effects 0.000 description 29
- 239000012530 fluid Substances 0.000 description 28
- 238000004891 communication Methods 0.000 description 23
- 239000006260 foam Substances 0.000 description 21
- 239000000463 material Substances 0.000 description 15
- 210000002683 foot Anatomy 0.000 description 13
- 229920003023 plastic Polymers 0.000 description 12
- 239000004033 plastic Substances 0.000 description 12
- 206010058490 Hyperoxia Diseases 0.000 description 10
- 230000000222 hyperoxic effect Effects 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 238000002266 amputation Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000002483 medication Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 6
- 210000004761 scalp Anatomy 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 5
- 206010056340 Diabetic ulcer Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 208000003790 Foot Ulcer Diseases 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 4
- 238000007373 indentation Methods 0.000 description 4
- 210000002414 leg Anatomy 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 4
- 238000006213 oxygenation reaction Methods 0.000 description 4
- -1 polyethylene Polymers 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 206010017543 Fungal skin infection Diseases 0.000 description 3
- 208000000558 Varicose Ulcer Diseases 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 208000004631 alopecia areata Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229960004039 finasteride Drugs 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 240000002989 Euphorbia neriifolia Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000035901 Ischaemic ulcer Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 229940064804 betadine Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229920002457 flexible plastic Polymers 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 229960002163 hydrogen peroxide Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000003273 male-pattern hair loss Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229940107889 rogaine Drugs 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- 206010001766 Alopecia totalis Diseases 0.000 description 1
- 206010001767 Alopecia universalis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000032775 alopecia universalis congenita Diseases 0.000 description 1
- 229960003204 amorolfine Drugs 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000003645 female-pattern hair loss Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 230000003699 hair surface Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012961 medicinal therapy Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940117382 propecia Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000003566 sealing material Substances 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940009188 silver Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000007892 surgical revascularization Methods 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009192 ultraviolet light therapy Methods 0.000 description 1
- 238000012783 upstream development Methods 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H35/00—Baths for specific parts of the body
- A61H35/006—Baths for specific parts of the body for the feet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
- A61H23/02—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
- A61H23/0218—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with alternating magnetic fields producing a translating or oscillating movement
- A61H23/0236—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with alternating magnetic fields producing a translating or oscillating movement using sonic waves, e.g. using loudspeakers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
- A61M16/16—Devices to humidify the respiration air
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/20—Non-portable devices, e.g. spraying booths
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
- A61M39/24—Check- or non-return valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0616—Skin treatment other than tanning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/06—Artificial hot-air or cold-air baths; Steam or gas baths or douches, e.g. sauna or Finnish baths
- A61H2033/068—Steam baths
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/14—Devices for gas baths with ozone, hydrogen, or the like
- A61H2033/143—Devices for gas baths with ozone, hydrogen, or the like with oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/01—Constructive details
- A61H2201/0173—Means for preventing injuries
- A61H2201/0184—Means for preventing injuries by raising an alarm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/02—Characteristics of apparatus not provided for in the preceding codes heated or cooled
- A61H2201/0207—Characteristics of apparatus not provided for in the preceding codes heated or cooled heated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/16—Physical interface with patient
- A61H2201/1602—Physical interface with patient kind of interface, e.g. head rest, knee support or lumbar support
- A61H2201/1654—Layer between the skin and massage elements, e.g. fluid or ball
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5023—Interfaces to the user
- A61H2201/5025—Activation means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5023—Interfaces to the user
- A61H2201/5043—Displays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5058—Sensors or detectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5058—Sensors or detectors
- A61H2201/5071—Pressure sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5058—Sensors or detectors
- A61H2201/5082—Temperature sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2230/00—Measuring physical parameters of the user
- A61H2230/20—Blood composition characteristics
- A61H2230/207—Blood composition characteristics partial O2-value
- A61H2230/208—Blood composition characteristics partial O2-value used as a control parameter for the apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0208—Oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
- A61M2205/3584—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using modem, internet or bluetooth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0652—Arrays of diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
Definitions
- the present disclosure relates in general to medical treatment systems. More particularly, the present disclosure relates to a medical treatment apparatus, methods of using the medical treatment apparatus and a system for treatment of medical conditions including bacterial and fungal infections, hair loss and surface wounds.
- Medical professionals and healthcare providers such as nurses and doctors routinely treat patients having various skin disorders including infected lesions, bacterial infections such as acne (i.e. Propionibacterium acnes ), fungal infections such as Athlete's foot (i.e. fungal genus Trichophyton ), conditions associated with hair loss including alopecia areata (patch baldness), alopecia totalis (complete baldness of the scalp) and alopecia universalis (body baldness) as well as ulcerations and frostbite resulting from poor circulation.
- Variations in skin disorders and other patient indications dictate variations in desired medications for treatment, such as antibiotics, growth factors, enzymes, hormones, protocols, such as delivery rates for medication and temperature control.
- Propionibacterium acnes causes acne vulgaris that is painful, causing seborrhea (scaly red skin), comedone (blackheads and whiteheads) and pimples often resulting in scarring and in extreme cases disfigurement. It is estimated that nearly 85% of people between the ages of 12 to 24 develop acne. Young men are more likely to suffer the effects of acne for longer periods of time then Young women because testosterone lends to make acne worse. In 2013, it was estimated that there were over 316 million people in the United States and approximately one third of those individuals were between the ages of 10 and 24.
- Athlete's foot also known as Tinea pedis is an inflammatory condition and represents the most common of all superficial fungal skin infections. Over 1 million individuals in the United States contract Athlete's loot each year. It is predominantly caused by a group of fungi called dermatophytes which includes Trichophyton rubrum, Trichophyton mentogrophytes var. interdigitale and Epidermophyton floccosum . For most patients, recurrent or chronic foot fungal infections are more of an inconvenience than a problem. Rarely is treatment sought. This may explain the high prevalence of the disease. Cellulitis is a more serious consequence of an untreated fungal foot infection.
- allylamines i.e. terbinafine
- imidazoles i.e. clotrimazole, ketoconazole, sulconazole and miconazole
- morpholine derivatives i.e. amorolfine
- Alopecia areata is a disorder that causes sudden hair loss on the scalp and other regions of the body. It affects more than 5 million Americans, 60% of them under the age of 20. It is not a health threat, but can be psychologically damaging, especially for children, to cope with baldness.
- Minoxidil more commonly known as Rogaine is a nonprescription medication approved for androgenetic alopecia and alopecia areata. In a liquid or foam, it is rubbed into the scalp twice a day.
- foot wounds in diabetic patients represent a significant public health problem throughout the world. Diabetes is a large and growing problem in the United Slates and worldwide, costing an estimated $45 billion dollars to the U.S. health care system. Patients afflicted with diabetes often have elevated glucose and lipid levels due to inconsistent use of insulin, which can result in a damaged circulatory system and high cholesterol levels. Often, these conditions are accompanied by deteriorating sensation in the nerves of the loot. As a result, diabetics experience a high number of non-healing foot ulcers.
- leg ulcers It is estimated that each year up to three million leg ulcers occur in patients in the U.S., including venous stasis ulcers, diabetic ulcers, ischemic leg ulcers, and pressure ulcers. The national cost of chronic wounds is estimated at $6 billion. Diabetic ulcers often progress to infections, osteomyelitis and gangrene, subsequently resulting in toe amputations, leg amputations, and death. In 1995, approximately 70,000 such amputations were performed at a cost of $23,000 per toe and $40,000 per limb. Many of these patients progress to multiple toe amputations and contralateral limb amputations. In addition, the patients are also at a greatly increased risk of heart disease and kidney failure from arteriosclerosis which attacks the entire circulatory system.
- the conventional methods of treatment for non-healing diabetic ulcers include wound dressings of various types, antibiotics, wound healing growth factors, skin grafting including tissue engineered grafts, use of wheelchairs and crutches to remove mechanical pressure, and finally amputation.
- surgical revascularization procedures via autografts and allografts and surgical laser revascularization have been applied with short term success, but with disappointing long term success due to reclogging of the grafts.
- antibiotics and thrombolytic anticoagulant and anti-aggregation drugs are often indicated. The failure to heal and the frequent recurrence of these ulcers points to the lack of success of these conventional methods. Accordingly, the medical community has a critical need for a low cost, portable, non-invasive method of treating diabetic, venous, ischemic and pressure ulcers to reduce mortality and morbidity and reduce the excessive costs to the health care system.
- foot wounds in patients with, for example, diabetes develop because of a process called neuropathy. Diabetes causes loss of sensation such that skin injury and complete breakdown (ulcer) can develop with no or minimal pain. These wounds tend not to heal because of ongoing mechanical trauma not felt at all by the patient as painful. Therefore, by the time the patient discovers the wound, the wound has often progressed so that the patient's treatment options have become severely limited.
- What is needed is a treatment that primary care physicians and their staff can employ to treat bacterial and fungal skin infections, hair loss, skin ulcers and other wounds that do not require extended physician time and that is effective even at later stages of the medical condition. Also, what is needed is a treatment that allows patients to be able to continue their active lives without the need to wear casts, or be confined to wheelchairs and crutches.
- a wound treatment apparatus in one embodiment, includes a treatment vessel having a treatment chamber and an opening to the treatment chamber that are sized to receive a human limb.
- a removable and substantially gas impermeable liner lines the chamber of the vessel and forms a treatment zone around the patient's limb.
- a cuff is removably coupled to the opening of the vessel and is sized to sealingly engage a human limb when the limb is inserted through the opening.
- a mixture tank holds a humidifying agent and is in fluid communication with the chamber of the vessel.
- a first array of light emitting diodes is coupled to the chamber and emits ultraviolet light into the chamber.
- a speaker is attached to the vessel and delivers low frequency sound waves to the chamber.
- a second array of light emitting diodes is coupled to the chamber and emits pulsed light into tire chamber.
- a wound treatment system includes a vessel that is sized to receive a human limb.
- the vessel includes a chamber with an opening leading into tire chamber.
- a removable liner lines tire chamber of the vessel and forms a treatment zone.
- a humidifier in fluid communication with the treatment zone humidifies a solution of water and antibacterial agent.
- An oxygen source is in fluid communication with tire treatment zone.
- a speaker is coupled to the vessel and emits low frequency sound waves to the chamber.
- a first array of light emitting diodes that emits ultraviolet light is coupled to the vessel near the opening of the treatment chamber.
- a second array of light emitting diodes that emits pulsed light into the chamber is coupled to the chamber.
- the system also includes a control panel.
- a wound treatment method for treating a wounded limb includes cleaning the wound.
- the method also includes disinfecting the limb by passing the limb through a ring of ultraviolet light emitting diodes that emit ultraviolet light on the limb as the limb passes through the ring.
- the limb is placed into a vessel having a chamber that is lined, with a substantially gas impermeable liner by passing the limb through a cuff that sealingly surrounds a portion of the limb, thus forming a substantially gas impermeable treatment zone around a portion of the limb distal the cuff.
- the limb is heated by introducing warm water into the chamber, which causes the inner liner to collapse around the patient's limb.
- the warm water is emptied out of the chamber, and a temperature controlled mist of topical hyperbaric oxygen, water and an antibacterial solution is introduced into the treatment zone.
- the limb is massaged by activating a speaker coupled to the vessel that transmits low frequency sound waves to the treatment zone.
- the limb is heated and kept warm by activating an array of light emitting diodes coupled to the vessel that emits pulsed light onto the limb.
- a method for treating an individual having a medical condition or an infection comprises the steps of (a) introducing a body pan of an individual having a medical condition or infection into a treatment chamber; (b) surrounding the body part in the treatment chamber with a mist containing water and a medication; and (c) surrounding the body part in tire treatment chamber with an O 2 -enriched gas without increasing the pressure around the body part to 22 mm Hg.
- the medical condition may be acne vulgaris resulting from infection by Propionibacterium acnes or Athlete's foot caused by a group of fungi of tire genus Trichophyton .
- the body pan may be the face or an appendage. More specifically, a hand, a forearm, a hand and forearm, a hand, forearm and upper arm, a foot, a calf, a foot and calf or a foot, calf and thigh.
- the medications may be general such as betadine, isopropyl alcohol, bacitracin, hydrogen peroxide, and combinations thereof.
- they may be specific for the infection, such as benzoyl peroxide, salicylic acid, glycolic acid, sulfur, azelaic acid or combinations thereof for the treatment of acne or 6-piperidin-1-ylpyrimidine-2,4-diamine 3-oxide (Minoxidil), N-(1,1-dimethylethyl)-3-oxo- ⁇ 5 ⁇ ,17 ⁇ )-4-azaandrost-1-ene-17-carboxamide (Finasteride), (11 ⁇ ,16 ⁇ )-9-fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione (Triamcinolone), 17-hydroxy-7 ⁇ -mercapto-3-oxo-17 ⁇ -pregn-4-ene-21-carboxylic acid, ⁇ -lactone acetate (Spironolactone) or combinations thereof for the treatment
- the treatment zone may receive an adiabatic mist comprised of water or water mixed with medication. This treatment may be followed by displacing the mist with oxygen-enriched gas. Alternatively, the gas may be pure oxygen. Tins process may be performed multiple times in a single treatment. Under one treatment method steps b and c are repeated four times in one treatment lasting 80 minutes.
- the one or more chambers may also be flooded with either one or both ultraviolet light and/or infrared light during treatment.
- a variable hyperoxia treatment apparatus in yet another aspect, includes one or more treatment chambers being sized to receive a human body part.
- a removable and substantially gas impermeable liner that lines each of said chambers and forms a treatment zone around the human body part.
- a mixture lank holds a humidifying agent and has a medicinal filling port for receiving medications to be mixed with the humidifying agent.
- the mixture tank is in fluid communication with the gas impermeable liners.
- the oxygen concentrator concentrates O 2 from the environment anti is provided with an O 2 dispensing port in gas tight communication with the gas impermeable liners.
- the one or more treatment chambers having an inlet port for receiving fluid and an outlet port for dispensing the fluid.
- variable hyperoxia treatment apparatus the electric components and mixture tank are separated from the oxygen concentrator and oxygen receiving port by the one or more treatment chambers.
- the oxygen components are housed in a container separated from the electric components.
- the variable hyperoxia treatment apparatus may further comprise a variety of other functional components.
- variable hyperoxia treatment apparatus may include a fluid connection between the humidifier and the mixture tank; an oxygen control valve; a pump that pumps water into and/or out of the one or more chambers; a cuff removably coupled to the opening of the one or more treatment chambers and sized to sealingly engage a human body part; a nasal cannula and/or facemask in communication with said oxygen concentrator for administering oxygen to an individual during treatment; a speaker that delivers low frequency sound waves to the one or more chambers when they contain water; ultraviolet and/or infrared light emitting diodes to illuminate the surface of the human body part; or a variety of sensors in fluid communication with the treatment zone such as a temperature sensor; a humidity sensor and/or a pressure sensor.
- the liner is made of a sterile or sterilizable plastic material and may further comprise a pressure release valve fluidly connecting the treatment zone with the one or more chambers; or one-way valves in fluid connection with the mixture tank and/or oxygen concentrator.
- the cuff may be made of an open cell material configured to naturally leak fluid forming a baffle for the treatment zone.
- a variable hyperoxia therapy treatment system is provided with a control panel for operating the system.
- One or more treatment chambers are provided, each having at least one opening and sized to receive a human body pan.
- a removable and substantially gas impermeable liner lines each of the chambers and forms a treatment zone around the human body part.
- a humidifier creates a mist from a solution of water that may include one or more medications and an oxygen source are both in fluid communication with the treatment zone.
- the oxygen received by the treatment zone may be provided by an outside oxygen source such as an oxygen tank or may be provided through the oxygen concentrator.
- the control panel comprises a master power switch and may be operated manually or automatically according to a predetermined regimen. If operated automatically, a plurality of automatic settings corresponding to a plurality of predetermined regimens may be utilized.
- one or more treatment chambers may be affixed securely to a human body part.
- a human body part may be inserted into one or more chambers for treatment.
- the system may further comprise a fluid source for filling the one or more chambers with fluid.
- variable hyperoxia therapy treatment system may further comprise an adiabatic humidifier, an ultrasonic energy source to form a mist from a solution of water that may include one or more medications; an oximeter, an O 2 concentrator, a wireless transmitter adapted to transmit data; a barcode data reader and/or a sensor in communication with a foam cuff that determines the position of the cuff when lilted about the human body part. The position establishes a volume range of humidified solution containing one or more medications to be dispensed into the liner for treatment of the body part.
- FIG. 1 is a three-dimensional view of a wound treatment system.
- FIG. 2 is a is an illustration of a control panel of a wound treatment system.
- FIG. 3A is another three-dimensional view of the wound treatment system depicted in FIG. 1 .
- FIG. 3B is a three dimensional view of the wound treatment system depicted in FIG. 1 with patient being treated.
- FIG. 4A is a three dimensional view of a lid assembly of a wound treatment system.
- FIG. 4B is a three dimensional view of a treatment vessel of a wound treatment system.
- FIG. 5 is a side exploded view of a treatment vessel of a wound treatment system.
- FIG. 6A is a front transparency view of the treatment vessel depicted in FIG. 5 .
- FIG. 6B is a top view of the wound treatment tank depicted in FIG. 5 .
- FIG. 7A is a front transparency view of a wound treatment chamber.
- FIG. 7B is a bottom view of the wound treatment chamber depicted in FIG. 7B .
- FIG. 8A is a rear view of a wound treatment system with a rear panel removed.
- FIG. 8B is another rear view of the wound treatment system depicted in FIG. 8B further depicting a humidifier.
- FIG. 9A is a front transparency view of a water reservoir used in a wound treatment system.
- FIG. 9B is a side transparency view of the water reservoir depicted in FIG. 9A .
- FIG. 10 is a side transparency view of one aspect of the variable hyperoxia therapy treatment system showing separation of the electrical components from the components that receive and dispense oxygen, an oxygen concentrator for collecting and administering oxygen to the liner and/or patient during treatment and the liner with separate openings and one-way valves for receiving mist from the humidifier and oxygen from the oxygen concentrator.
- FIG. 11 shows optional adapters that may be connected to the variable hyperoxia therapy treatment system in FIG. 10 to treat areas of the body that cannot be inserted into the central chamber of the device such as the back and scalp.
- the apparatus, systems, and methods described herein provide hyperbaric oxygen to open, chronic wounds as an adjunct therapy in wound management and treatment.
- they can also provide mild heat, gentle massage, infrared and ultraviolet light therapy, moisture therapy, and application of antibacterial agents. These features are intended to promote the rate of healing and suppression of bacterial growth.
- a wound treatment system 10 which generally includes a topical oxygen chamber for limbs and is intended to surround a patient's limb and apply humidified water, antibacterial agent, and oxygen topically at a pressure slightly greater than atmospheric pressure.
- the wound treatment system 10 includes a rectangular, rigid plastic carriage 15 having a treatment vessel 800 forming a chamber 810 (shown in FIG. 5 ) that is sized to accommodate a patient's limb, particularly a patient's foot and a portion of the leg up to the knee.
- a padded leg rest 18 supports the patient's leg during treatment sessions.
- the system also includes a control panel 30 , a cart 40 housing a first reservoir 600 for water, an adiabatic humidifier 400 that holds a solution of water and antibacterial agent, a water pump 500 (all shown in FIGS. 8A and 8B ), and a control box (beneath the control panel) that houses the circuit boards that control the system 10 .
- a mist control valve unit 50 is attached to a back panel of the cart 40 .
- a hose 70 connects the mist control valve unit 50 to the vessel 20
- one or more hoses 71 connect the humidifier 400 to the mist control valve unit 50 .
- a lid assembly 60 (shown in FIGS. 1 and 4A ) that includes a first lower lid 61 that is hinged to the vessel 800 at the proximal end 64 of the vessel 800 opposite the end abutting the back panel of the cart 40 .
- the lower lid 61 includes a circular opening 161 that provides access to a chamber 810 firmed inside the vessel.
- the lid assembly 60 also includes a second upper lid that is formed by two opposing covers 62 and 63 .
- Cover 62 covers the distal side 64 of the vessel 800 and cover 63 covers the proximal side 65 of the vessel 800 .
- the covers 62 and 63 are completely removable from the top of the vessel 800 .
- the distal side of cover 63 forms a half circular indentation that is matched by a half circular indentation in the proximal side of cover 62 so that when the distal side of cover 63 and the proximal side of cover 62 join, a found opening 169 is formed when the covers 62 and 63 are secured over lid 61 .
- Each cover 62 and 63 has a raised half circular wall 67 and 68 projecting vertically from its kip surface around its corresponding half circular indentation.
- the walls 67 and 68 join to form a cylinder 69 .
- the round opening 169 formed when the half circular indentations are joined is concentric with the circular opening 161 of the lower lid 61 so that a patient's limb can project down through the cylinder 69 , through opening 169 formed by the covers 62 and 63 , through opening 161 of the lower lid 61 , and into the chamber 830 of the vessel 20 .
- An oxygen inlet port 77 on the cover 62 receives a hose 78 connected to an oxygen source, such as an oxygen tank or a central oxygen source in a hospital.
- the inlet port 77 can include a fitting (not shown) to sealingly secure the hose 78 to the cover 62 .
- the cover 62 includes a vapor inlet port 72 that receives the hose 70 .
- the vapor inlet port 72 can include a fitting 73 to sealingly secure the hose 70 to the vapor inlet port 72 .
- Either of the covers 62 or 63 can also include a temperature sensor 92 , a humidity sensor 94 , and a pressure sensor 96 , each of which are in fluid communication with a treatment zone formed by a treatment bag 100 sealed to the lid 61 of the vessel ( FIG. 4B ).
- the cart 40 includes wheels 41 at each corner to mobilize the system 10 .
- the control panel 30 includes a display with various knobs and switches that controls the operation of the wound treatment system 10 .
- the panel includes controls 130 that control the humidifier, controls 140 that control an array of ultraviolet light emitting diodes (LEDs) 310 (see FIGS. 4A and 4B ) controls 150 that control an array or board of infrared light 880 (see FIGS. 4B, 6A, and 7A ) and an audio transducer or speaker 870 (see FIGS. 5, 6A, 7A, and 7B ), controls 160 that control a water pump 500 (see FIG. 8A ), and controls 170 that control the master power for the system 10 .
- LEDs ultraviolet light emitting diodes
- the humidifier functions of the system are controlled by controls 130 , which include at least some of the following: an on/off switch 131 that turns on the humidifier function; a button 132 that can be used to manually activate or open the mist control valve unit 50 and that illuminates when the mist control valve unit 50 is open and allowing the flow of therapeutic mist into the chamber 830 ; a button 133 that opens an electronic oxygen flow valve in the tubing 78 connected to the oxygen source and illuminates when the oxygen flow valve is open and allowing oxygen flow into the chamber 810 ; an auto/manual switch 134 that sets the humidifier function to either manual operation or auto operation; a mist timer knob 135 that is used to set the amount of time for mist flow into the chamber 810 ; and an oxygen timer knob 136 that sets the amount of time for oxygen flow into the chamber 810 .
- controls 130 include at least some of the following: an on/off switch 131 that turns on the humidifier function; a button 132 that can be used to manually activate or open the mist control
- the UV functions of the system is controlled by controls 140 , which include at least some of the following: an on/off switch 141 that turns on the UV function; a foot in button 142 that illuminates when the patient inserts his foot through the opening 169 —the collar 300 can have a sensor 360 that senses the foot and sends a signal back to the control box to activate the UV LEDS; a UV on button 143 that can be depressed to manually activate the UV LEDS 310 and that illuminates when the UV LEDS 310 are activated; an auto/manual switch 144 that sets the UV function to cither manual operation or auto operation; and an UV timer knob 145 that sets the amount of time that the UV LEDS will remain on once they are activated.
- controls 140 include at least some of the following: an on/off switch 141 that turns on the UV function; a foot in button 142 that illuminates when the patient inserts his foot through the opening 169 —the collar 300 can have a sensor 360 that senses the foot and sends a signal back to the control box to
- the IR/Audio functions of the system is controlled by controls 150 , which include at least some of the following: an on/off switch 151 that turns on the IR/Audio function: an IR button 152 that can be used to manually activate the IR LEDS and that illuminates when the IR LEDS and speaker are operating; an Audio, button 153 that can be used to manually activate the speaker or audio transducer and that illuminates when the speaker is operating: an auto/manual switch 154 that sets the IR/Audio function to either manual operation or auto operation; and a timer knob 155 dial sets the amount of time that the IR LEDS and speaker will remain on once they are activated.
- controls 150 include at least some of the following: an on/off switch 151 that turns on the IR/Audio function: an IR button 152 that can be used to manually activate the IR LEDS and that illuminates when the IR LEDS and speaker are operating; an Audio, button 153 that can be used to manually activate the speaker or audio transducer and that illuminates
- the pump control functions of the system is controlled by controls 160 , which include at least some of the following: an an/off switch 161 that turns on the pump control function; a drain button 162 that can be used to manually operate the timing of drainage or the chamber 810 and that illuminates when the chamber 810 is draining; a fill button 163 that can be used to manually operate the timing of filling the chamber 810 with warm water and that illuminates when the chamber is filling with water; and an auto/manual switch 164 that sets the pump control function to either manual operation or auto operation.
- the master control buttons 170 include at least some of the following: a master control switch 171 that turns the system on and off; a start button 171 that is used to start the operation of the system and that illuminates when the system is operating; and a stop button 172 that can be depressed to prematurely stop the operation of the system.
- control panel 30 also includes a thermostat (not shown) that is electrically coupled to a submergible water heater 680 (see FIG. 9A ) that is located in the water reservoir tank 600 .
- the thermostat can be used to control the temperature of the water that is pumped from the water reservoir tank 600 into the chamber 810 .
- the system 10 works by switching the master power switch 170 to the on position, which turns the system on and puts the system in ready mode.
- the healthcare provider decides which of the functions will be used in the specific regimen for the particular patient.
- the regimen may provide for operation of all of the functions, or just some of the functions.
- a regimen may call for warming the limb with injection of warm water into the chamber and then treating the wound with the antibiotic mist, but may not require infrared treatment and low frequency sound vibrations.
- all of the on/off switches would be switched to the one position except for the IR/Audio control switch 151 , which would remain in the off position.
- the mist timer knob 135 and oxygen timer knob 136 can then be set to operate for the appropriate amount of time. According to one embodiment, the mist can be set at about fifteen minutes, while the oxygen is set at about five minutes.
- the UV timer knob 145 is set to operate for an appropriate amount of time. According to one embodiment, the UV timer is set to operate for less than 5 seconds, less than 4 seconds, less than 3 seconds, less than 2 seconds, or less than 1 second.
- the IR/Audio timer can be set to operate for a period of lime coinciding with the warm water bath of the limb, which is when the chamber is filled with warm water, which warms the limb. This period can last from about one minute to about ten minutes or more. All of the auto/manual switches can be set to auto for a predetermined and default regimen. Next the healthcare provider depresses the start button 171 , which begins the regimen.
- the system when all of the functions are in operation and auto modes, and the start button 171 is depressed, the system operates as follows. First the system waits for the sensor 360 to detect the insertion of a limb of a patient P, as shown in FIG. 3B ) into the chamber 810 . Alter the wound in the limb is cleaned, the limb is inserted through the opening 169 of the covers 62 and 63 and the opening 161 of the lid 61 . The sensor 360 detects the limb as it passes through the opening 161 and activates the UV function, which activates the ring of UV LEDs 310 located concentrically around the opening 161 . The UV LEDS 310 briefly stimulate the limb (about one to five seconds) as it passes through the opening of the chamber 810 and then the UV LEDs 310 deactivate. The UV on button 143 illuminates while the UV LEDs are on.
- a cuff 90 is placed around the limb and the lids 62 and 63 closed around the cuff 90 so that the half circular walls 67 and 68 form a substantial seal around the cuff.
- the cuff will be discussed in more detail later.
- the limb is placed in a bag or liner 100 that is substantially impermeable to gas.
- the top opening of the bag 100 is sealed to the bottom surf ace of the lid 61 and forms an airtight seal with the bottom surface of the lid 61 .
- the pump 500 is activated and pumps warm water from the water reservoir 600 to the chamber 810 of the vessel 800 through a hose 510 that is connected to an outlet port 660 in the reservoir 600 on one end and the pump 500 on the other end.
- Another hose 520 carries the water from the pump 500 to a water pipe protruding from the vessel 20 that is connected to an opening in the chamber 810 .
- the water pump 500 shuts off automatically after a predetermined amount of water is drained from the reservoir 600 .
- the warm water entering the chamber 810 causes the bag 100 to collapse around the limb and creates a warm southing sensation on the limb.
- the warm water bath remains in the chamber 810 for a predetermined amount of time, generally between about one minute and ten minutes or more.
- the array of IR LEDs 880 in the chamber 810 is activated and transmits a pulsed (or steady) IR light during the warm water bath.
- the IR LEDS further warm the limb increasing circulation.
- the audio transducer or speaker 870 is activated and generates a low frequency sound wave that surrounds the limb. This creates a massaging effect, stimulates the skin and further enhances circulation.
- the water pump 500 is then activated in reverse and the warm water is pumped out of the chamber 810 and back into the reservoir 600 .
- the IR LEDs 880 and the audio transducer 870 are turned off.
- mist control valve unit 50 An adiabatically-humidified, temperature-controlled vapor of water and a topical antibacterial, antiseptic or antibiotic agent is released from the humidifier 400 by mist control valve unit 50 .
- the vapor travels through the tube 70 and, enters the treatment none through a port 72 in the lid 62 , which is substantially sealed to the lube 70 .
- the vapor hydrates the wound and provides antibacterial effects.
- This vapor treatment can last between about two minutes and about thirty minutes, depending on the timer 135 set by the healthcare provider. In one embodiment, vapor treatment lasts about fifteen minutes.
- the mist control valve unit 50 is activated to close the valve between the humidifier 400 and the tube 70 .
- the oxygen release valve is opened and oxygen flows from the oxygen source, which can either be an oxygen tank as shown or a wall mounted oxygen unit connected to a central oxygen source, such as in a hospital setting (not shown).
- the oxygen flows through the tube 78 into an oxygen inlet port 77 on the surface of the lid 62 .
- the oxygen displaces the vapor and oxygenates the wound.
- Oxygenation can last between about one minute and about fifteen minutes. In one embodiment, oxygenation lasts about five minutes.
- the process between vapor treatment and oxygenation can be repeated several times. In one embodiment, vapor treatment and oxygenation are repeated three times for a total of four rounds of treatment lasting approximately eighty minutes.
- the patient's oxygen level can be monitored during treatment using an oximeter connected to the patients finger or other body part.
- the oximeter can be electrically connected to the control circuits in the control box of the system 10 , and a display can warn the user to stop treatment or introduction of oxygen if the patient's blood oxygen level is too low or too high according to a predetermined level, such as below 80% saturation for an extended period of time.
- An extended period of time can be two or more minutes.
- FIG. 3A shows the wound treatment system 10 with the control panel 30 lid removed and the lid 61 opened. Underneath the lid of the control panel reside the various electronics and circuitry of the system 10 .
- a 12V power supply 220 can be used to power the system.
- a sweep function generator 210 is used to generate a low frequency waveform for the audio function.
- the sweep function generator 210 can generate an adjustable frequency of between about 1 Hz and about 1000 Hz. It can generate various types of waveforms, such as sweeping waveforms and ramping waveforms within that range of frequencies.
- the sweep function generator 210 produces a sin wave signal that is transmitted to the audio amplifier 230 , which can be a 12V amplifier.
- the amplifier 230 amplifies, the signal to about 50 W and transmits the amplified signal to the speaker or audio transducer 870 connected to the vessel 800 .
- the sweep function generator 220 can be preset to a default frequency and waveform. In one embodiment, it can be preset to generate a 60 Hz signal, which can be manually altered to produce a signal at other frequencies between the range of about 1 Hz and about 1000 Hz.
- An assembly control cable 240 connects the control box (not shown) with the electronic components of the system.
- the control box (not shown) which is housed underneath the control panel lid 30 , houses all of the circuit boards required to operate the system 10 .
- a circular collar 300 that forms a perimeter around the opening 161 on the bottom surface 61 B of the lid 61 .
- An array of UV LEDs 310 is mounted on the inner surface of the collar forming a ring. The UV LEDs 310 each point toward the center of the opening 161 . There can be as few as four LEDS and as many as one hundred twenty or more LEDs in the array of UV LEDs 310 .
- the array of UV LEDs 310 can deliver 330 W of UVA at about 320 nm to about 400 nm.
- the array of UV LEDs 310 can deliver 330 W of UVB at about 290 nm to about 320 nm.
- the array of UV LEDs 310 can deliver 330 W of UVC at about 100 nm to about 200 nm.
- the collar 300 also includes a motion sensor 360 to detect when a limb has been inserted through the collar and the ring of UV LEDs 310 .
- the motion sensor is connected to the control box through a wire 312 that is threaded through a bole in the collar and then a hole in the bottom of the carriage 15 and up through the bottom of the cart 40 .
- the wire 312 is eventually bundled in the cable 240 and carries an electrical signal to the circuitry in the control box.
- the array of UV LEDs 310 receives its electrical signals front the control box through a wire 311 that is also threaded through the hole in the collar and then a hole in the bottom of the carriage 15 and up through the bottom of the cart 40 and eventually bundled in the cable 240 .
- the lid 61 is raised by lifting the distal side of the lid while the proximal side pivots along its hinges.
- Chains or wires 85 are connected at one of their ends to the bottom surface 61 B of the lid 61 and at their other ends to the back panel of the cart with hooks or oilier securement means.
- the lid 61 falls back and is supported by the chains 85 .
- the bottom surface 61 B of the lid 61 includes a gasket 184 around its square or rectangular perimeter that seals the bottom surface 61 B of the lid 61 to the vessel 800 when the lid 61 is closed.
- the lid 61 can have a substantially circular crown 350 projecting vertically from its upper surface 340 .
- This crown is in lieu of the collar 300 shown in FIGS. 3A and 4B .
- the array of UV LEDs 310 is coupled to the inside surface of the crown 350 , as is the motion detector 360 .
- the upper lid is formed by covers 62 and 63 .
- Each of the covers 62 and 63 can form a corresponding half washer shaped raised portion 62 and 63 . Projecting vertically from the center of each raised portion 62 and 63 is a half circular wall 67 and 68 .
- the washer shaped raised portions 62 and 63 join to form a raised washer shaped portion that fits over the circular crown 350 to form a substantial seal between the outer wall of the crown 350 and the inner wall of the washer shaped raised portion.
- the outer wall of the crown 350 can include a gasket (not shown) to reinforce the seal.
- the half circular walls 67 and 68 also join to form a cylinder with an opening 169 in the center that is concentric with and open to the opening 161 of the lid 61 .
- An oxygen inlet port 77 on the washer shaped raised portion 62 receives a hose (not shown) connected to an oxygen source, such as an oxygen lank or a central oxygen source in a hospital.
- the oxygen inlet port 77 can include a fitting (not shown) to sealingly secure the hose to the cover raised portion 62 .
- the raised portion 62 includes a vapor inlet port 72 that receives the hose 70 (shown in FIG. 1 ).
- the vapor inlet port 72 can include a fitting 73 (shown in FIG. 1 ) to sealingly secure the hose 70 to the vapor inlet port 72 .
- a liner or bag 100 (as shown in FIGS. 3A and 4B ) into which the patient's limb is placed; and a foam cuff 90 (as shown in FIGS. 3B and 4A ), which is placed around the patient's limb.
- the liner 100 forms a treatment zone around the wound and makes contact with the open wound. Therefore, it is preferable that the liner 100 be biocompatible and sterile.
- the liner 100 can be discarded or sterilized after each use and/or replaced with a new or sterilized liner 100 .
- the material from which the liner 100 is made can be any strong substantially gas impermeable material.
- Extruded flexible plastic film material such as polyethylene (hdpe, ldpe, lldpe, polyprolene, etc.), polyurethane ether or ester open cell foam (e.g., United States Plastics Corp. Stock No. 47134), polyethylene terephthalate, polyvinyl chloride, or ethylene/polyvinyl copolymer sleet stock, and vapor proof treated fabric, such as nylon, are suitable.
- the material can be puncture resistant and transparent.
- the flexible sheet material can have a variety of shapes. It can be a single layer, such as a bag to surround a limb, or have multiple layers.
- the bag or liner 100 may also be co or tri axially oriented.
- substantially gas impermeable means gas impermeable to the extent needed to prevent excessive gas escape from the treatment zone through the sheet material. Total gas impermeability seldom is needed, particularly for continuous flow treatment devices. However, generally high impermeability is desirable for static treatment devices.
- the perimeter of the opening of the liner 100 can have an adhesive strip with a removable backing.
- the backing can be removed und the perimeter of the lining can be substantially sealed against the crown 350 (or the collar 300 ), thus forming a scaled connection between the perimeter of the opening of the liner 100 and the lid 61 .
- the liner 100 can be taped to the crown 350 (or the collar 300 ) to form a substantial seal between the lid 61 and the liner 100 .
- the liner 100 includes a pressure release valve 103 built into it.
- the design of the pressure release valve 105 is not critical. Many different types are suitable.
- the valve 105 can be a ball valve or a baffle valve such as a flap or butterfly baffle valve. Other valves are equally suitable, so long as they are capable of accurately setting the maximum release pressure and are inexpensive and so discardable.
- the adjustable valve 105 can be calibrated to show the pressure setting.
- the maximum release pressure can be set at 22 mm of mercury so that the pressure inside the liner 100 never surpasses that amount of pressure.
- the valve body can be made of any rigid plastic, although metals such as stainless steel can be used also.
- the spring can be steel or plastic. Very inexpensive completely plastic valves can be used as well.
- the pressure release valves 105 integrated with the liner 100 are inexpensive yet reliably accurate, within the preferred accuracy ranges. If desired, they can be removed from a used liner 100 and reused on new liners. Using a valve that is in communication with the treatment zone and not with the gas supply eliminates the need for a separate pressure control mechanism between the chamber 810 and the oxygen source.
- the chamber 810 can be connected directly to a gas or oxygen tank or a hospital gas supply line.
- a foam cuff 90 is placed around the patient's limb and inserted concentrically with the cylinder formed by the half circular walls 67 and 68 .
- the foam cuff 90 can be disjoined so that it can be opened and placed around a limb.
- the foam cuff 90 can be made of a biocompatible open cell material that is compressible and resilient and forms a substantial seal or baffle between the patient's limb and the cylinder formed by the walls 67 and 68 .
- the open cell configuration prevents rapid fluid leakage through the cuff, but does allow for some fluid leakage at pressures approaching 22 mm of mercury, tints acting as a baffle.
- the pressure inside the treatment zone should not reach 22 mm of mercury, and the fluid leakage through the foam cuff 90 as the pressure inside the treatment zone increases will prevent pressures from building up beyond that level.
- a pressure release valve 105 in the liner 100 may not be necessary.
- the foam cuff 90 can also include a backing cm its outer non-skin contacting surface that can be peeled away, exposing a sticky surface that sticks to the cylinder.
- the foam cuff 90 can be made of a polyurethane ester or a natural material.
- FIGS. 5-7B show the vessel 800 in which the patient's wound is treated.
- the vessel 800 sits inside of the rigid plastic carriage 15 shown in FIG. 1 .
- the vessel 800 is formed by inserting chamber 810 into tank 830 .
- the outer dimensions of the chamber 810 are slightly smaller than the inner dimensions of the tank 830 so that the chamber 810 is nested securely within the tank 830 .
- the only dimension of the tank 830 that is substantially different from the chamber 810 is that the tank 830 is several inches deeper than the chamber 810 .
- This provides for extra mom at the bottom of the lank 830 for the audio transducer or speaker 870 connected to the bottom of the chamber 810 , so that when the chamber 810 is placed in the tank 830 , the top edges 812 and 832 of the chamber 810 and tank 830 are substantially coplanar as shown in FIG. 6A .
- the tank 830 is made of a molded plastic or metal that is rigid and durable. As shown in FIGS. 6A and 6B , the tank 830 has a foam platform 835 forming an inner bottom surface of the tank 830 .
- the foam platform 835 has a circular pipe hole 836 cut into it that receives the audio transducer or speaker 870 .
- the foam platform 835 has a second pipe hole 837 cut into it that is matched up with a hole 838 cut in the bottom of the tank 830 to form an outlet port for the water pipe 818 projecting vertically downward from the bottom surface of the chamber 810 .
- Bolts 833 projecting vertically downward from the bottom of the tank 830 are used to guide and connect the tank 830 to the carriage 13 .
- the chamber 810 includes a scaling member 813 that surrounds the chamber just beneath its edge 812 .
- the sealing member 813 forms a substantially fluid-tight seal between the chamber 810 and the tank 830 .
- Inside the dumber 810 is an IR board 880 with an array of IR LEDs.
- the board 880 has bolts 881 on its corners that are used to bolt the board 880 to the bottom of the chamber 810 .
- PCB wiring 881 is coupled to the IR board 880 and exits from the chamber 810 through hole 882 drilled into the bottom of the chamber 810 .
- the hole 882 can be drilled at a location beneath the IR board 880 and can be about 1 ⁇ 4 inch.
- Silicone, hot glue, and/or other sealing materials can be used to form a fluid tight seal between the wiring 881 and the hole 882 to seal the chamber 810 , hardware, and wires front leaks.
- the wiring 881 is lead through the pipe hole 837 in the tank 830 and connects with a connection to the control box.
- the IR board 880 includes IR LEDs arranged in a pattern on a square or rectangular board.
- the IR LEDs can emit energy at infrared frequencies of between about 700 nm and 30,000 nm.
- the IR board 880 can be controlled by the control panel to adjust the frequency.
- the IR LEDs deliver about 2000 mW of infrared light at about 810 nm.
- tire IR board 880 can also generate about 1.2 W of Red light at about 660 nm for a combined total light output of 1911 mW.
- the IR board 880 can be a Thor DDII IR Lamp System.
- a hole is drilled through the bottom of the chamber 810 , and the water pipe 818 is inserted through the hole, projecting vertically downward through the hole and out the bottom of the chamber 810 .
- a tub seal pipe coupling 819 is used to form a fluid tight seal between the pipe 818 and the hole through which it is inserted through the chamber 810 .
- the water pipe 818 is open at both ends to allow water to flow in and out of the chamber 810 when the chamber 810 is connected to the reservoir 600 through a water hose.
- an audio transducer or speaker 870 coupled to the outside of the chamber at the bottom of the chamber 810 is an audio transducer or speaker 870 .
- the speaker 870 is bolted to the bottom of the chamber 810 .
- Transducer wires 876 are connected to the speaker 870 and, like the IR wiring, are threaded through the pipe hole 837 in the lank 830 to form a connection with the control box.
- a rigid plastic or metal collar 890 with a hole 892 is placed around the speaker 870 to protect the speaker 870 .
- the speaker 870 emits energy at a low frequency sound wave, of between about 1 Hz and about 1000 Hz. In one embodiment, the speaker emits energy at about 60 Hz. This causes a therapeutic vibration on the chamber 830 and a massaging effect on the patient's limb.
- the foam platform 835 is a premolded piece that is inserted into the bottom of the tank 810 , and the chamber 810 is placed on top of the foam 835 .
- a hardening foam gel is poured into the bottom of the tank 810 to a predetermined depth, and the chamber 810 with speaker 870 and collar 890 are quickly placed into the tank 810 .
- the foam gel hardens around the pipe 838 and wires 881 and 876 , the collar 890 , and the bottom of the chamber 810 .
- the tank 830 is ultimately bolted to the rigid plastic carriage 15 .
- FIGS. 8A and 8B the components of the wound treatment system 10 that are housed in the can 40 are shown.
- FIGS. 8A and 8B are front views of the cart 40 looking at the cart 40 from the direction of viewing the control panel 30 .
- FIG. 8A shows the components with the humidifier 400 removed so that the water pump 500 is visible.
- FIG. 3B shows the components with the humidifier 4410 in its normal position blocking a view of the pump 500 , which sits behind the humidifier 400 .
- a warm water reservoir 600 rests on a shelf 43 at the bottom of the cart 40 .
- a first hose 510 is connected to the water pump 500 through lilting 512 .
- the other end of the hose 510 is secured to a hose fitting 630 (shown in FIG. 9B ) laterally projecting from the reservoir 600 so that the hose is in fluid communication with the inside of the reservoir 600 .
- a second hose 520 is connected to the water pump 500 through fitting 522 .
- the oilier end of hose 520 is connected to the water pipe 818 projecting vertically from the bottom of the vessel 800 so that the hose 520 is in fluid communication with the inside of the chamber 810 .
- Cables 510 electrically couple the water pump to the control box.
- the reservoir 600 has a rigid lid 610 dial can, be removed to expose the inside of the reservoir and fill it with water.
- the reservoir 600 includes two float switches 640 and 650 .
- An upper float switch 640 is used to determine when the reservoir 600 is full and a lower float switch 650 is used to determine when the reservoir 600 is empty.
- Switch 640 has a lead 642 that is electrically connected to terminal block 660 with wire 645 .
- Switch 650 has a lead 652 that is electrically connected to terminal block 660 with wire 655 .
- Terminal block 660 is electrically connected to the pump with wires 670 .
- the spacing between the switches 640 and 650 determines the amount of water that will be pumped into the chamber 830 when the system 10 is activated and the pump function is operating.
- the switches 640 and 650 are arranged so dial the optimal amount of water is pumped into the chamber 830 . If too much water is pumped into the chamber, the lid 61 can dislodge causing the chamber 830 to leak. If there isn't enough water, the patients limb will not be warmed enough. In one embodiment, about five gallons of water is pumped from the reservoir 600 to the chamber 830 . When the pump function is activated, the pump begins to pump water 500 out of the reservoir 600 through fitting 660 . When the water level reaches the lower switch 650 and the floating arm 653 of the switch 650 begins to dip fall, an electrical signal is transmitted to the pump 500 through wires 670 , and the pump 500 automatically shuts oil.
- the pump 500 When the drain function is activated, the pump 500 begins to pump in reverse, draining the water from the chamber 830 and back into the reservoir 600 .
- the water in the reservoir reaches the upper switch 650 and the floating arm 643 of the switch 640 begins to rise, an electrical signal is transmitted to the pump 500 through wires 670 , and the pump automatically turns off.
- the water is kept at an optimal temperature with a portable healing unit 680 that is adjustable between a range of about 70.degree. F. and about 90.degree. F.
- a more sophisticated heating unit is used (not shown) that is electrically coupled to the control box and can be controlled with a thermostat in the control panel 30 .
- the humidifier unit 400 sits atop the lid 610 of the reservoir 600 .
- the humidifier has a removable lid 410 dial can be removed to fill the reservoir of the humidifier 400 with water and an antibacterial agent, such as ionic silver, hydrogen peroxide, bacitracin, betadine, or isopropyl alcohol.
- an antibacterial agent such as ionic silver, hydrogen peroxide, bacitracin, betadine, or isopropyl alcohol.
- adiabatically humidified 1% hydrogen peroxide/silver solution is used, but other FDA approved topical antibacterial, antibiotic, antiseptics and antimicrobial solutions and agents, such as those described above, may also be used.
- the humidifier 400 has a misting unit that constantly produces mist as long as the humidifier function on the control panel 30 is activated.
- the misting unit can be an adiabatic temperature controlled humidifier or ultrasonic nebulizer.
- the humidifier 400 can generate room temperature mist or heated mist. It can include a built-in heater (not shown) with an on/off switch and an indicator light that shows that the heater is on and at operating temperature.
- Warm mist temperature in the bag 100 can teach between about 77.degree. F. and about 82.degree. F. as measured with a temperature gauge in the lid assembly.
- the humidity in the bag 100 can reach about 89% to about 91% as measured by a humidity gauge.
- the humidifier has a transducer that generates ultrasonic energy at about 40 kHz, to create an adiabatic/humid mist that creates a cloud. Ultrasonic energy from the misting unit is not transmitted to the limb, which is about two feet away from the misting unit.
- the valve control unit 50 When the valve control unit 50 is opened, the mist travels from the humidifier 400 into the exit tube 410 and out through the exit port 420 where it enters the valve control unit 50 . From there the mist travels through the tube 70 and into the treatment zone formed by the bag 100 surrounding the patient's limb.
- variable hyperoxia treatment apparatus as shown in FIG. 10 , provides at least one treatment chamber for receiving a body part that separates the electronic components of the apparatus from the oxygen supply and concentrator.
- Many of the component parts of this apparatus are similar or identical to those discussed in previous embodiments and aspects.
- a majority of the electrical components of the apparatus are isolated from the oxygen source and the components that deliver oxygen to the treatment chamber and the patient.
- the water fill port 975 , the medicine fill port 970 , the adiabatic humidifier 980 , the ultrasound device 982 , the humidifier control valve 984 , the control panel 962 , the temperature sensor 952 , the pressure sensor 950 , the humidity sensor 986 , the lid sensor 928 , the electrical connections to the UV/IR LED arrays 924 are preferably on one side of the treatment chamber while the oxygen intake port 946 , oxygen control valve 940 , oxygen concentrator 942 and oxygen delivery ports 948 are on the other side of the treatment chamber.
- the oxygen intake port 946 , oxygen control valve 940 , oxygen concentrator 942 and oxygen delivery ports 948 may be securely housed in a separate chamber isolated from electronic components of the apparatus but not separated by the treatment chamber.
- UV and IR LEDs 942 that irradiate the surface of the body part are mounted to the chamber. There may be as few as five LEDS one mounted to illuminate the front, one for the back, one for the left side, one for the right side and one for the base of the body part. Alternatively, there may be arrays 942 of ten to several hundred positioned similarly to irradiate the entire body pan in the treatment chamber.
- the array of UV LEDs 942 can deliver 330 W of UVA at about 320 nm to about 400 nm. Alternatively, or in addition to, the array of UV LEDs 942 can deliver 330 W of UVB at about 290 nm to about 320 nm.
- the array of UV LEDs 942 can deliver 330 W of UVC at about 100 nm to about 200 nm. In one embodiment, there are ninety UV LEDs delivering 330 W of UVA at about 374 nm to about 392 nm, delivering a total of about 324 mW or 324 W.
- the IR board includes IR LEDs 942 arranged in a pattern about the chamber.
- the IR LEDs 942 can emit energy at infrared frequencies of between about 700 nm and 50,000 nm.
- the IR LEDs 942 can be controlled by the control panel 962 to adjust the frequency.
- the IR LEDs 942 delivers about 2000 mW of infrared light at about 810 nm.
- the IR LEDs 942 can also generate about 1.2 W of red light at about 660 nm fix a combined total light output of 1911 mW.
- the IR LEDs 942 can be a Thor DDII IR Lamp System.
- the programmed treatment also sends electrical signals from the control box to the arrays of UV/IR LEDs 942 through a wire that is also threaded through die device and eventually bundled in the cable leading to the control panel 962 .
- the lid is provided as a two-piece circular collar 926 that forms a perimeter around the opening of the treatment chamber. Sliding apart the two pieces of the circular collar 926 opens the lid.
- the lid also includes a sensor 928 to detect the diameter of the body part that has been inserted through the collar 926 .
- the sensor 928 wire is threaded through the device and eventually bundled in the cable leading to the control panel 962 .
- the diameter of the body part is relayed to a processor in the control panel 962 that establishes the amount of humidified mist and oxygen that will be applied to the body part for each step of the programmed treatment.
- An oxygen inlet port 946 receives a hose (not shown) connected to an oxygen source, such as an oxygen lank or a central oxygen source in a hospital.
- the oxygen inlet port 946 allows oxygen to flow from the source to an oxygen flow meter 944 in communication with the oxygen concentrator 942 .
- the oxygen concentrator 942 and/or oxygen flow meter 944 is in communication with the liner 900 through a one-way valve 940 allowing control of oxygen to tire treatment zone.
- the oxygen concentrator 942 and/or oxygen flow meter is also in communication with a cannula or facemask that may be worn by the patient during treatment.
- the oxygen supply line hose may be sealingly affixed to an inlet port 946 on tire side of the apparatus (not shown) which is directly connected to the oxygen flow meter 944 and/or oxygen concentrator 942 .
- the liner 900 forms a treatment zone around the wound and makes contact with the open wound. Therefore, it is preferable that the liner 900 be biocompatible and sterile.
- the liner 900 can be discarded or sterilized after each use and/or replaced with a new or sterilized liner 900 .
- the material from which the liner 900 is made can be any strong substantially gas impermeable material. Extruded flexible plastic film material, such as polyethylene (hdpe, ldpe, lldpe, polyprolene, etc,), polyurethane ether or ester open cell foam (e.g., United States Plastics Gap. Stock No.
- the liner 900 also has at least two one-way inlet valves 940 at or about its base for receiving mist/medicated mist from the humidifier 980 and oxygen from the oxygen flow meter 944 and/or oxygen concentrator 942 .
- the design of the one way valves 940 is not critical. A variety of different types may be utilized.
- the liner 900 may also have an outlet port (not shown) that may be utilized for allowing replacement of agents in the treatment zone with fresh or other agents during the programmed treatment.
- the perimeter of the opening of the liner 900 can have an adhesive strip with a removable backing. The backing is removed and the perimeter of the lining substantially is sealed against the two-pieces of the collar 926 tints terming a sealed connection between the perimeter of the opening of the liner 900 and the lid.
- the liner 900 may have a foam rim or cuff 916 about the opening with a drawstring, so foam rim 916 provides a comfortable seal around the body part being treated when the drawstring is tightened.
- the liner 900 may also have a pressure release valve 914 .
- the design of the pressure release valve 914 is not critical. Many different types are suitable.
- tire valve 914 can be a ball valve or a baffle valve such as a flap or butterfly baffle valve. Other valves are equally suitable, so long as they are capable of accurately setting the maximum release pressure.
- the adjustable valve can be calibrated to show the pressure setting. In one embodiment, the maximum release pressure can be set at 22 mm Hg so that the pressure inside the liner 900 never surpasses that amount of pressure.
- the valve body is preferably made of any in expensive rigid plastic.
- an audio transducer or speaker 960 Coupled to the bottom of the chamber on its outside surface is an audio transducer or speaker 960 .
- Transducer wires are connected to the speaker and threaded through the apparatus to form a connection with the control panel 962 .
- a rigid plastic or metal collar with a hole is placed around the speaker 960 to protect the speaker 960 during use.
- the speaker 960 emits energy at a low frequency sound wave, of between about 1 Hz and about 1000 Hz. In one embodiment, the speaker 960 emits energy at about 60 Hz. This causes a therapeutic vibration on the chamber and a massaging effect on the patient's body part.
- the components or the variable hyperoxia treatment apparatus are housed in a cart.
- a warm water reservoir 995 is contained at the bottom of the cart.
- a first hose is connected to the water pump 990 and the other end of the hose is secured and in fluid communication with the inside of the one or more chambers.
- a second hose (not shown) is connected to the water pump 990 and the other end of hose can be connected to a waste container or drain. Cables electrically couple the water pump to the control box.
- the reservoir 995 provides an opening that allows the reservoir to be filled with water.
- the water may be kept at an optimal temperature with a portable heating unit (not shown) that is adjustable between a range of about 70° F. to about 90° F.
- a (tearing unit within the apparatus may be used (not shown) that is electrically coupled to the control panel 962 and can be controlled with a thermostat in the control panel 962 .
- the humidifier 980 is positioned above the warm water reservoir 995 .
- the humidifier 980 is in fluid communication with a water reservoir 975 that has a removable lid to enable filling with fluid and/or medication.
- a medication reservoir 970 for receiving medications and/or medication dosage is in fluid communication with the humidifier 980 so that it may be mixed with fluid to create an adiabatic vapor or mist for treatment.
- the humidifier 980 produces mist when the humidifier function on the control panel 962 is activated.
- the misting unit can be an adiabatic temperature controlled humidifier 980 or ultrasonic nebulizer 982 .
- the humidifier 980 can generate room temperature mist or heated mist, live humidifier may further comprise a temperature controller 954 with an on/off switch and an indicator light that shows when the temperature controller 954 is on and at operating temperature.
- the humidifier control valve 984 to the humidifier 980 is opened, the mist travels from the humidifier 980 into the treatment zone through a one-way valve in the liner 900 .
- Warm mist temperature in the liner 900 can reach between about 77° F. to about 82° F. as measured by a temperature sensor.
- the humidity in the liner 900 can reach about 89% to about 91% as measured by a humidity sensor 986 .
- the humidifier 980 has a transducer that generates ultrasonic energy in the ultrasonic nebulizer 982 at about 40 kHz to create an adiabatic/humid mist. Ultrasonic energy from the misting unit is not transmitted to the limb.
- the oxygen flow meter 944 and concentrator 942 and humidifier 980 are also in fluid communication with an outlet port that is in fluid communication 916 with a treatment chamber remote to the cart.
- the treatment chamber 910 / 914 ( FIG. 11 ) comprises a pre-molded form adapted to encompass a non-limb body part such as a scalp, a thigh or the back.
- the chamber 910 / 914 is composed of a semi-rigid polymer having a cushioned perimeter edge for sealingly engaging the body pan. Its configuration will depend on the area being treated. For example, a half domed shape may be desired for treating a particular location on the back while a helmet shaped dumber would be desirable for treating the scalp.
- the chamber may have at least two inlet ports, one for the humidified mist from the humidifier 980 and one for oxygen from the oxygen flow meter 944 and/or oxygen concentrator 942 . There may be an additional outlet port (not shown) to allow for replacing the existing agents in the chamber with new or other agents.
- the treatment clumber 910 / 914 may further comprise UV/IR USDs for illuminating the treatment area.
- the U V/IR LEDs are in electrical communication with the control panel 962 . This electrical communication line may be affixed to or integrated within tubing 912 and has a connector near adapters 916 for connecting to the control pane) 962 .
- a disposable or autoclavable liner 900 having at least two one-way ports at 940 and 984 for receiving humidified mist and oxygen lines the chamber.
- the liner 900 may also have a pressure release valve 914 .
- the perimeter edge of the liner 900 may have adhesive for affixing the liner 900 to the rim of the chamber before use.
Abstract
Description
- None
- The present disclosure relates in general to medical treatment systems. More particularly, the present disclosure relates to a medical treatment apparatus, methods of using the medical treatment apparatus and a system for treatment of medical conditions including bacterial and fungal infections, hair loss and surface wounds.
- Medical professionals and healthcare providers such as nurses and doctors routinely treat patients having various skin disorders including infected lesions, bacterial infections such as acne (i.e. Propionibacterium acnes), fungal infections such as Athlete's foot (i.e. fungal genus Trichophyton), conditions associated with hair loss including alopecia areata (patch baldness), alopecia totalis (complete baldness of the scalp) and alopecia universalis (body baldness) as well as ulcerations and frostbite resulting from poor circulation. Variations in skin disorders and other patient indications dictate variations in desired medications for treatment, such as antibiotics, growth factors, enzymes, hormones, protocols, such as delivery rates for medication and temperature control.
- A vast majority of bacteria are harmless or beneficial. However, there are a few that are pathogenic. One such bacteria, Propionibacterium acnes causes acne vulgaris that is painful, causing seborrhea (scaly red skin), comedone (blackheads and whiteheads) and pimples often resulting in scarring and in extreme cases disfigurement. It is estimated that nearly 85% of people between the ages of 12 to 24 develop acne. Young men are more likely to suffer the effects of acne for longer periods of time then Young women because testosterone lends to make acne worse. In 2013, it was estimated that there were over 316 million people in the United States and approximately one third of those individuals were between the ages of 10 and 24. With close to 100 million suffering from acne in the US alone the skin care industry for the past fifty or so rears has been developing treatments with limited success. Currently, most medications include one or more of the following chemicals: benzoyl peroxide, salicylic acid, glycolic acid, sulfur and azelaic acid. However, because most individuals skin is unique it is difficult to find the appropriate formulation that will relieve or eliminate acne. Consequently, many individuals do not obtain proper treatment and are left to suffer with acne and often have scaring as a result. The need for a proper treatment is evidenced by individuals spending over 78 billion dollars on skin care worldwide in 2010 with facial care capturing 64% of this market.
- Athlete's foot also known as Tinea pedis is an inflammatory condition and represents the most common of all superficial fungal skin infections. Over 1 million individuals in the United States contract Athlete's loot each year. It is predominantly caused by a group of fungi called dermatophytes which includes Trichophyton rubrum, Trichophyton mentogrophytes var. interdigitale and Epidermophyton floccosum. For most patients, recurrent or chronic foot fungal infections are more of an inconvenience than a problem. Rarely is treatment sought. This may explain the high prevalence of the disease. Cellulitis is a more serious consequence of an untreated fungal foot infection. Although treatable, it can be a limb-threatening disease for patients with comorbidities, individuals with diabetes have an increased risk of developing this complication. The frequent outcome for this group is hospitalization and an increased length of stay when compared to their non-diabetic counterparts.
- There are three main groups of topical agents for treating fungal skin infections, allylamines (i.e. terbinafine), imidazoles (i.e. clotrimazole, ketoconazole, sulconazole and miconazole) and morpholine derivatives (i.e. amorolfine). All have been demonstrated to be more effective than placebo. However, their speed of action varies making compliance difficult and often resulting in ineffective treatment.
- Alopecia, or hair loss, effects approximately 35 million men and 21 million women in the United States. Alopecia areata is a disorder that causes sudden hair loss on the scalp and other regions of the body. It affects more than 5 million Americans, 60% of them under the age of 20. It is not a health threat, but can be psychologically damaging, especially for children, to cope with baldness. Of men being treated for Alopecia approximately 85% are being treated with Minoxidil and approximately 15% are being treated with Finasteride. Minoxidil more commonly known as Rogaine is a nonprescription medication approved for androgenetic alopecia and alopecia areata. In a liquid or foam, it is rubbed into the scalp twice a day. This is the most effective method to treat male-pattern and female-pattern hair loss. However, only 30-40% of patients experience hair growth and it is not effective for other causes of hair loss. Hair regrowth can take 8 to 12 months and treatment must be continued indefinitely because hair loss resumes if treatment is stopped. Finasteride (Propecia) is used in male-pattern hair loss in a pill form taken on a daily basis. It is not indicated for women and is not recommended in pregnant women. Treatment is effective within six to eight months of treatment. Side effects include decreased libido, erectile dysfunction, ejaculatory dysfunction, gynecomastia, and myopathy. Treatment should be continued as long as positive results occur. Once treatment is stopped, hair loss resumes again. In 2013, it is anticipated that men will spend over $225 million on medicinal therapies like Rogaine. Unfortunately, the low percentage of success, potential side effects and lifetime treatment regimen make this option difficult for many individuals.
- Another particular area of concern involves foot or limb wounds in diabetic patients. It is known that foot wounds in diabetic patients represent a significant public health problem throughout the world. Diabetes is a large and growing problem in the United Slates and worldwide, costing an estimated $45 billion dollars to the U.S. health care system. Patients afflicted with diabetes often have elevated glucose and lipid levels due to inconsistent use of insulin, which can result in a damaged circulatory system and high cholesterol levels. Often, these conditions are accompanied by deteriorating sensation in the nerves of the loot. As a result, diabetics experience a high number of non-healing foot ulcers.
- It is estimated that each year up to three million leg ulcers occur in patients in the U.S., including venous stasis ulcers, diabetic ulcers, ischemic leg ulcers, and pressure ulcers. The national cost of chronic wounds is estimated at $6 billion. Diabetic ulcers often progress to infections, osteomyelitis and gangrene, subsequently resulting in toe amputations, leg amputations, and death. In 1995, approximately 70,000 such amputations were performed at a cost of $23,000 per toe and $40,000 per limb. Many of these patients progress to multiple toe amputations and contralateral limb amputations. In addition, the patients are also at a greatly increased risk of heart disease and kidney failure from arteriosclerosis which attacks the entire circulatory system.
- The conventional methods of treatment for non-healing diabetic ulcers include wound dressings of various types, antibiotics, wound healing growth factors, skin grafting including tissue engineered grafts, use of wheelchairs and crutches to remove mechanical pressure, and finally amputation. In the case of ischemic ulcers, surgical revascularization procedures via autografts and allografts and surgical laser revascularization have been applied with short term success, but with disappointing long term success due to reclogging of the grafts. In the treatment of patients with venous stasis ulcers and severe venous disease, antibiotics and thrombolytic anticoagulant and anti-aggregation drugs are often indicated. The failure to heal and the frequent recurrence of these ulcers points to the lack of success of these conventional methods. Accordingly, the medical community has a critical need for a low cost, portable, non-invasive method of treating diabetic, venous, ischemic and pressure ulcers to reduce mortality and morbidity and reduce the excessive costs to the health care system.
- Most problematic of all is that treatment of diabetic foot ulcers has been focused on amputation and not on limb salvage, as many of the wounds have not been properly treated. Improper treatment can be attributed to lack of an easy and inexpensive treatment system and method and severe inconvenience to the patient in using current methods. There is a need to prevent amputation by healing such wounds, particularly at an early stage.
- Furthermore, amputation for conditions such as foot ulcers and frostbite becomes less avoidable the longer tire condition is either left untreated or is unsuccessfully treated. Therefore, it is crucial to apply an effective treatment regimen as soon as possible. Unfortunately, foot wounds in patients with, for example, diabetes develop because of a process called neuropathy. Diabetes causes loss of sensation such that skin injury and complete breakdown (ulcer) can develop with no or minimal pain. These wounds tend not to heal because of ongoing mechanical trauma not felt at all by the patient as painful. Therefore, by the time the patient discovers the wound, the wound has often progressed so that the patient's treatment options have become severely limited.
- In many cases, such wounds can only be healed by protecting them from mechanical trauma. Small plantar ulcers in diabetic patients area usually seen by primary cate practitioners and endocrinologists. The present method for healing plantar ulcers is a total contact cast for the foot, which provides complete mechanical protection. This method is not ideally suited fix either of these practice settings, because it requires skilled and specialized care in application, along with frequent follow up. Most patients perceive the cast to be an inconvenience at the early stages of such a wound, while perceiving that such a wound is not a serious matter. The alternative to the cast is to ask the patient to be non-weight bearing through the use of a wheelchair, crutches, or a walker, which provide complete mechanical protection only with complete patient compliance. This alternative rarely proves to be effective in healing wounds within a reasonable time period.
- What is needed is a treatment that primary care physicians and their staff can employ to treat bacterial and fungal skin infections, hair loss, skin ulcers and other wounds that do not require extended physician time and that is effective even at later stages of the medical condition. Also, what is needed is a treatment that allows patients to be able to continue their active lives without the need to wear casts, or be confined to wheelchairs and crutches.
- In one embodiment, a wound treatment apparatus includes a treatment vessel having a treatment chamber and an opening to the treatment chamber that are sized to receive a human limb. A removable and substantially gas impermeable liner lines the chamber of the vessel and forms a treatment zone around the patient's limb. A cuff is removably coupled to the opening of the vessel and is sized to sealingly engage a human limb when the limb is inserted through the opening. A mixture tank holds a humidifying agent and is in fluid communication with the chamber of the vessel. A first array of light emitting diodes is coupled to the chamber and emits ultraviolet light into the chamber. A speaker is attached to the vessel and delivers low frequency sound waves to the chamber. A second array of light emitting diodes is coupled to the chamber and emits pulsed light into tire chamber.
- A wound treatment system includes a vessel that is sized to receive a human limb. The vessel includes a chamber with an opening leading into tire chamber. A removable liner lines tire chamber of the vessel and forms a treatment zone. A humidifier in fluid communication with the treatment zone humidifies a solution of water and antibacterial agent. An oxygen source is in fluid communication with tire treatment zone. A speaker is coupled to the vessel and emits low frequency sound waves to the chamber. A first array of light emitting diodes that emits ultraviolet light is coupled to the vessel near the opening of the treatment chamber. A second array of light emitting diodes that emits pulsed light into the chamber is coupled to the chamber. The system also includes a control panel.
- A wound treatment method for treating a wounded limb is also described. The method includes cleaning the wound. The method also includes disinfecting the limb by passing the limb through a ring of ultraviolet light emitting diodes that emit ultraviolet light on the limb as the limb passes through the ring. The limb is placed into a vessel having a chamber that is lined, with a substantially gas impermeable liner by passing the limb through a cuff that sealingly surrounds a portion of the limb, thus forming a substantially gas impermeable treatment zone around a portion of the limb distal the cuff. The limb is heated by introducing warm water into the chamber, which causes the inner liner to collapse around the patient's limb. The warm water is emptied out of the chamber, and a temperature controlled mist of topical hyperbaric oxygen, water and an antibacterial solution is introduced into the treatment zone. The limb is massaged by activating a speaker coupled to the vessel that transmits low frequency sound waves to the treatment zone. The limb is heated and kept warm by activating an array of light emitting diodes coupled to the vessel that emits pulsed light onto the limb.
- In another aspect, a method for treating an individual having a medical condition or an infection is provided. The method comprises the steps of (a) introducing a body pan of an individual having a medical condition or infection into a treatment chamber; (b) surrounding the body part in the treatment chamber with a mist containing water and a medication; and (c) surrounding the body part in tire treatment chamber with an O2-enriched gas without increasing the pressure around the body part to 22 mm Hg.
- The medical condition may be acne vulgaris resulting from infection by Propionibacterium acnes or Athlete's foot caused by a group of fungi of tire genus Trichophyton. The body pan may be the face or an appendage. More specifically, a hand, a forearm, a hand and forearm, a hand, forearm and upper arm, a foot, a calf, a foot and calf or a foot, calf and thigh.
- The medications may be general such as betadine, isopropyl alcohol, bacitracin, hydrogen peroxide, and combinations thereof. Alternatively, they may be specific for the infection, such as benzoyl peroxide, salicylic acid, glycolic acid, sulfur, azelaic acid or combinations thereof for the treatment of acne or 6-piperidin-1-ylpyrimidine-2,4-diamine 3-oxide (Minoxidil), N-(1,1-dimethylethyl)-3-oxo-<5α,17β)-4-azaandrost-1-ene-17-carboxamide (Finasteride), (11β,16α)-9-fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione (Triamcinolone), 17-hydroxy-7α-mercapto-3-oxo-17α-pregn-4-ene-21-carboxylic acid, γ-lactone acetate (Spironolactone) or combinations thereof for the treatment of Athlete's foot.
- The treatment zone may receive an adiabatic mist comprised of water or water mixed with medication. This treatment may be followed by displacing the mist with oxygen-enriched gas. Alternatively, the gas may be pure oxygen. Tins process may be performed multiple times in a single treatment. Under one treatment method steps b and c are repeated four times in one treatment lasting 80 minutes.
- The one or more chambers may also be flooded with either one or both ultraviolet light and/or infrared light during treatment.
- In yet another aspect, a variable hyperoxia treatment apparatus is provided that includes one or more treatment chambers being sized to receive a human body part. A removable and substantially gas impermeable liner that lines each of said chambers and forms a treatment zone around the human body part. A mixture lank holds a humidifying agent and has a medicinal filling port for receiving medications to be mixed with the humidifying agent. The mixture tank is in fluid communication with the gas impermeable liners. The oxygen concentrator concentrates O2 from the environment anti is provided with an O2 dispensing port in gas tight communication with the gas impermeable liners. The one or more treatment chambers having an inlet port for receiving fluid and an outlet port for dispensing the fluid.
- In one configuration of use variable hyperoxia treatment apparatus, the electric components and mixture tank are separated from the oxygen concentrator and oxygen receiving port by the one or more treatment chambers. Alternatively, the oxygen components are housed in a container separated from the electric components. In addition, the variable hyperoxia treatment apparatus may further comprise a variety of other functional components. For example, the variable hyperoxia treatment apparatus may include a fluid connection between the humidifier and the mixture tank; an oxygen control valve; a pump that pumps water into and/or out of the one or more chambers; a cuff removably coupled to the opening of the one or more treatment chambers and sized to sealingly engage a human body part; a nasal cannula and/or facemask in communication with said oxygen concentrator for administering oxygen to an individual during treatment; a speaker that delivers low frequency sound waves to the one or more chambers when they contain water; ultraviolet and/or infrared light emitting diodes to illuminate the surface of the human body part; or a variety of sensors in fluid communication with the treatment zone such as a temperature sensor; a humidity sensor and/or a pressure sensor.
- The liner is made of a sterile or sterilizable plastic material and may further comprise a pressure release valve fluidly connecting the treatment zone with the one or more chambers; or one-way valves in fluid connection with the mixture tank and/or oxygen concentrator.
- In other embodiments of this aspect of the invention, the cuff may be made of an open cell material configured to naturally leak fluid forming a baffle for the treatment zone.
- In still another aspect of the invention, a variable hyperoxia therapy treatment system is provided with a control panel for operating the system. One or more treatment chambers are provided, each having at least one opening and sized to receive a human body pan. A removable and substantially gas impermeable liner lines each of the chambers and forms a treatment zone around the human body part. A humidifier creates a mist from a solution of water that may include one or more medications and an oxygen source are both in fluid communication with the treatment zone. The oxygen received by the treatment zone may be provided by an outside oxygen source such as an oxygen tank or may be provided through the oxygen concentrator.
- The control panel comprises a master power switch and may be operated manually or automatically according to a predetermined regimen. If operated automatically, a plurality of automatic settings corresponding to a plurality of predetermined regimens may be utilized.
- In one embodiment of this aspect of the invention, one or more treatment chambers may be affixed securely to a human body part. Alternatively, a human body part may be inserted into one or more chambers for treatment. In addition, the system may further comprise a fluid source for filling the one or more chambers with fluid.
- In another embodiment of this aspect of the invention, the variable hyperoxia therapy treatment system may further comprise an adiabatic humidifier, an ultrasonic energy source to form a mist from a solution of water that may include one or more medications; an oximeter, an O2 concentrator, a wireless transmitter adapted to transmit data; a barcode data reader and/or a sensor in communication with a foam cuff that determines the position of the cuff when lilted about the human body part. The position establishes a volume range of humidified solution containing one or more medications to be dispensed into the liner for treatment of the body part.
- Other aspects of the invention are found throughout tire specification.
- These and other features and advantages will be apparent from the following more particular description thereof, presented in conjunction with the following drawings, wherein:
-
FIG. 1 is a three-dimensional view of a wound treatment system. -
FIG. 2 is a is an illustration of a control panel of a wound treatment system. -
FIG. 3A is another three-dimensional view of the wound treatment system depicted inFIG. 1 . -
FIG. 3B is a three dimensional view of the wound treatment system depicted inFIG. 1 with patient being treated. -
FIG. 4A is a three dimensional view of a lid assembly of a wound treatment system. -
FIG. 4B is a three dimensional view of a treatment vessel of a wound treatment system. -
FIG. 5 is a side exploded view of a treatment vessel of a wound treatment system. -
FIG. 6A is a front transparency view of the treatment vessel depicted inFIG. 5 . -
FIG. 6B is a top view of the wound treatment tank depicted inFIG. 5 . -
FIG. 7A is a front transparency view of a wound treatment chamber. -
FIG. 7B is a bottom view of the wound treatment chamber depicted inFIG. 7B . -
FIG. 8A is a rear view of a wound treatment system with a rear panel removed. -
FIG. 8B is another rear view of the wound treatment system depicted inFIG. 8B further depicting a humidifier. -
FIG. 9A is a front transparency view of a water reservoir used in a wound treatment system. -
FIG. 9B is a side transparency view of the water reservoir depicted inFIG. 9A . -
FIG. 10 is a side transparency view of one aspect of the variable hyperoxia therapy treatment system showing separation of the electrical components from the components that receive and dispense oxygen, an oxygen concentrator for collecting and administering oxygen to the liner and/or patient during treatment and the liner with separate openings and one-way valves for receiving mist from the humidifier and oxygen from the oxygen concentrator. -
FIG. 11 shows optional adapters that may be connected to the variable hyperoxia therapy treatment system inFIG. 10 to treat areas of the body that cannot be inserted into the central chamber of the device such as the back and scalp. - The apparatus, systems, and methods described herein provide hyperbaric oxygen to open, chronic wounds as an adjunct therapy in wound management and treatment. In addition, per determination by the healthcare providers that use the described apparatus, systems, and methods, they can also provide mild heat, gentle massage, infrared and ultraviolet light therapy, moisture therapy, and application of antibacterial agents. These features are intended to promote the rate of healing and suppression of bacterial growth.
- Turning to
FIG. 1 , awound treatment system 10 is shown, which generally includes a topical oxygen chamber for limbs and is intended to surround a patient's limb and apply humidified water, antibacterial agent, and oxygen topically at a pressure slightly greater than atmospheric pressure. Thewound treatment system 10 includes a rectangular, rigidplastic carriage 15 having atreatment vessel 800 forming a chamber 810 (shown inFIG. 5 ) that is sized to accommodate a patient's limb, particularly a patient's foot and a portion of the leg up to the knee. Apadded leg rest 18 supports the patient's leg during treatment sessions. The system also includes acontrol panel 30, acart 40 housing afirst reservoir 600 for water, anadiabatic humidifier 400 that holds a solution of water and antibacterial agent, a water pump 500 (all shown inFIGS. 8A and 8B ), and a control box (beneath the control panel) that houses the circuit boards that control thesystem 10. A mistcontrol valve unit 50 is attached to a back panel of thecart 40. Ahose 70 connects the mistcontrol valve unit 50 to the vessel 20, and one ormore hoses 71 connect thehumidifier 400 to the mistcontrol valve unit 50. - Covering the
vessel 800 is a lid assembly 60 (shown inFIGS. 1 and 4A ) that includes a firstlower lid 61 that is hinged to thevessel 800 at theproximal end 64 of thevessel 800 opposite the end abutting the back panel of thecart 40. Thelower lid 61 includes acircular opening 161 that provides access to achamber 810 firmed inside the vessel. - The
lid assembly 60, as shown inFIGS. 1 and 4A , also includes a second upper lid that is formed by two opposingcovers Cover 62 covers thedistal side 64 of thevessel 800 and cover 63 covers theproximal side 65 of thevessel 800. Thecovers vessel 800. The distal side ofcover 63 forms a half circular indentation that is matched by a half circular indentation in the proximal side ofcover 62 so that when the distal side ofcover 63 and the proximal side ofcover 62 join, a foundopening 169 is formed when thecovers lid 61. Eachcover circular wall FIG. 1 , thewalls cylinder 69. Theround opening 169 formed when the half circular indentations are joined is concentric with thecircular opening 161 of thelower lid 61 so that a patient's limb can project down through thecylinder 69, throughopening 169 formed by thecovers lower lid 61, and into thechamber 830 of the vessel 20. - An
oxygen inlet port 77 on the cover 62 (or alternatively cover 63) receives ahose 78 connected to an oxygen source, such as an oxygen tank or a central oxygen source in a hospital. Theinlet port 77 can include a fitting (not shown) to sealingly secure thehose 78 to thecover 62. Thecover 62 includes avapor inlet port 72 that receives thehose 70. Thevapor inlet port 72 can include a fitting 73 to sealingly secure thehose 70 to thevapor inlet port 72. Either of thecovers temperature sensor 92, ahumidity sensor 94, and apressure sensor 96, each of which are in fluid communication with a treatment zone formed by atreatment bag 100 sealed to thelid 61 of the vessel (FIG. 4B ). Thecart 40 includeswheels 41 at each corner to mobilize thesystem 10. - As shown in
FIG. 2 , thecontrol panel 30 includes a display with various knobs and switches that controls the operation of thewound treatment system 10. The panel includescontrols 130 that control the humidifier, controls 140 that control an array of ultraviolet light emitting diodes (LEDs) 310 (seeFIGS. 4A and 4B ) controls 150 that control an array or board of infrared light 880 (seeFIGS. 4B, 6A, and 7A ) and an audio transducer or speaker 870 (seeFIGS. 5, 6A, 7A, and 7B ), controls 160 that control a water pump 500 (seeFIG. 8A ), and controls 170 that control the master power for thesystem 10. - The humidifier functions of the system are controlled by
controls 130, which include at least some of the following: an on/offswitch 131 that turns on the humidifier function; abutton 132 that can be used to manually activate or open the mistcontrol valve unit 50 and that illuminates when the mistcontrol valve unit 50 is open and allowing the flow of therapeutic mist into thechamber 830; abutton 133 that opens an electronic oxygen flow valve in thetubing 78 connected to the oxygen source and illuminates when the oxygen flow valve is open and allowing oxygen flow into thechamber 810; an auto/manual switch 134 that sets the humidifier function to either manual operation or auto operation; amist timer knob 135 that is used to set the amount of time for mist flow into thechamber 810; and anoxygen timer knob 136 that sets the amount of time for oxygen flow into thechamber 810. - The UV functions of the system is controlled by
controls 140, which include at least some of the following: an on/offswitch 141 that turns on the UV function; a foot inbutton 142 that illuminates when the patient inserts his foot through theopening 169—thecollar 300 can have asensor 360 that senses the foot and sends a signal back to the control box to activate the UV LEDS; a UV onbutton 143 that can be depressed to manually activate theUV LEDS 310 and that illuminates when theUV LEDS 310 are activated; an auto/manual switch 144 that sets the UV function to cither manual operation or auto operation; and anUV timer knob 145 that sets the amount of time that the UV LEDS will remain on once they are activated. - The IR/Audio functions of the system is controlled by
controls 150, which include at least some of the following: an on/offswitch 151 that turns on the IR/Audio function: anIR button 152 that can be used to manually activate the IR LEDS and that illuminates when the IR LEDS and speaker are operating; an Audio,button 153 that can be used to manually activate the speaker or audio transducer and that illuminates when the speaker is operating: an auto/manual switch 154 that sets the IR/Audio function to either manual operation or auto operation; and atimer knob 155 dial sets the amount of time that the IR LEDS and speaker will remain on once they are activated. - The pump control functions of the system is controlled by
controls 160, which include at least some of the following: an an/offswitch 161 that turns on the pump control function; adrain button 162 that can be used to manually operate the timing of drainage or thechamber 810 and that illuminates when thechamber 810 is draining; afill button 163 that can be used to manually operate the timing of filling thechamber 810 with warm water and that illuminates when the chamber is filling with water; and an auto/manual switch 164 that sets the pump control function to either manual operation or auto operation. - The
master control buttons 170 include at least some of the following: amaster control switch 171 that turns the system on and off; astart button 171 that is used to start the operation of the system and that illuminates when the system is operating; and astop button 172 that can be depressed to prematurely stop the operation of the system. - In one embodiment, the
control panel 30 also includes a thermostat (not shown) that is electrically coupled to a submergible water heater 680 (seeFIG. 9A ) that is located in thewater reservoir tank 600. The thermostat can be used to control the temperature of the water that is pumped from thewater reservoir tank 600 into thechamber 810. - In operation, the
system 10 works by switching themaster power switch 170 to the on position, which turns the system on and puts the system in ready mode. The healthcare provider then decides which of the functions will be used in the specific regimen for the particular patient. Depending on the patient and the ailment, the regimen may provide for operation of all of the functions, or just some of the functions. For example, a regimen may call for warming the limb with injection of warm water into the chamber and then treating the wound with the antibiotic mist, but may not require infrared treatment and low frequency sound vibrations. Thus, all of the on/off switches would be switched to the one position except for the IR/Audio control switch 151, which would remain in the off position. When operating under normal conditions, all of the functions can be turned on by switching all of the on/off switches to the on position. This sets all of the functions to ready mode. Themist timer knob 135 andoxygen timer knob 136 can then be set to operate for the appropriate amount of time. According to one embodiment, the mist can be set at about fifteen minutes, while the oxygen is set at about five minutes. TheUV timer knob 145 is set to operate for an appropriate amount of time. According to one embodiment, the UV timer is set to operate for less than 5 seconds, less than 4 seconds, less than 3 seconds, less than 2 seconds, or less than 1 second. The IR/Audio timer can be set to operate for a period of lime coinciding with the warm water bath of the limb, which is when the chamber is filled with warm water, which warms the limb. This period can last from about one minute to about ten minutes or more. All of the auto/manual switches can be set to auto for a predetermined and default regimen. Next the healthcare provider depresses thestart button 171, which begins the regimen. - According to one embodiment, when all of the functions are in operation and auto modes, and the
start button 171 is depressed, the system operates as follows. First the system waits for thesensor 360 to detect the insertion of a limb of a patient P, as shown inFIG. 3B ) into thechamber 810. Alter the wound in the limb is cleaned, the limb is inserted through theopening 169 of thecovers opening 161 of thelid 61. Thesensor 360 detects the limb as it passes through theopening 161 and activates the UV function, which activates the ring ofUV LEDs 310 located concentrically around theopening 161. TheUV LEDS 310 briefly stimulate the limb (about one to five seconds) as it passes through the opening of thechamber 810 and then theUV LEDs 310 deactivate. The UV onbutton 143 illuminates while the UV LEDs are on. - Next, a
cuff 90 is placed around the limb and thelids cuff 90 so that the halfcircular walls liner 100 that is substantially impermeable to gas. The top opening of thebag 100 is sealed to the bottom surf ace of thelid 61 and forms an airtight seal with the bottom surface of thelid 61. Thus, when the limb is surrounded by thecuff 90, which is surrounded by the halfcircular walls - Once the limb is secured as described, the
pump 500 is activated and pumps warm water from thewater reservoir 600 to thechamber 810 of thevessel 800 through ahose 510 that is connected to anoutlet port 660 in thereservoir 600 on one end and thepump 500 on the other end. Anotherhose 520 carries the water from thepump 500 to a water pipe protruding from the vessel 20 that is connected to an opening in thechamber 810. Thewater pump 500 shuts off automatically after a predetermined amount of water is drained from thereservoir 600. The warm water entering thechamber 810 causes thebag 100 to collapse around the limb and creates a warm southing sensation on the limb. The warm water bath remains in thechamber 810 for a predetermined amount of time, generally between about one minute and ten minutes or more. The array ofIR LEDs 880 in thechamber 810 is activated and transmits a pulsed (or steady) IR light during the warm water bath. The IR LEDS further warm the limb increasing circulation. - Also contemporaneous with the activation with the
IR LEDs 880, the audio transducer orspeaker 870 is activated and generates a low frequency sound wave that surrounds the limb. This creates a massaging effect, stimulates the skin and further enhances circulation. Thewater pump 500 is then activated in reverse and the warm water is pumped out of thechamber 810 and back into thereservoir 600. TheIR LEDs 880 and theaudio transducer 870 are turned off. - An adiabatically-humidified, temperature-controlled vapor of water and a topical antibacterial, antiseptic or antibiotic agent is released from the
humidifier 400 by mistcontrol valve unit 50. The vapor travels through thetube 70 and, enters the treatment none through aport 72 in thelid 62, which is substantially sealed to thelube 70. The vapor hydrates the wound and provides antibacterial effects. This vapor treatment can last between about two minutes and about thirty minutes, depending on thetimer 135 set by the healthcare provider. In one embodiment, vapor treatment lasts about fifteen minutes. Then the mistcontrol valve unit 50 is activated to close the valve between thehumidifier 400 and thetube 70. - At this time, the oxygen release valve is opened and oxygen flows from the oxygen source, which can either be an oxygen tank as shown or a wall mounted oxygen unit connected to a central oxygen source, such as in a hospital setting (not shown). The oxygen flows through the
tube 78 into anoxygen inlet port 77 on the surface of thelid 62. The oxygen displaces the vapor and oxygenates the wound. Oxygenation can last between about one minute and about fifteen minutes. In one embodiment, oxygenation lasts about five minutes. The process between vapor treatment and oxygenation can be repeated several times. In one embodiment, vapor treatment and oxygenation are repeated three times for a total of four rounds of treatment lasting approximately eighty minutes. The patient's oxygen level can be monitored during treatment using an oximeter connected to the patients finger or other body part. The oximeter can be electrically connected to the control circuits in the control box of thesystem 10, and a display can warn the user to stop treatment or introduction of oxygen if the patient's blood oxygen level is too low or too high according to a predetermined level, such as below 80% saturation for an extended period of time. An extended period of time can be two or more minutes. -
FIG. 3A shows thewound treatment system 10 with thecontrol panel 30 lid removed and thelid 61 opened. Underneath the lid of the control panel reside the various electronics and circuitry of thesystem 10. A12V power supply 220 can be used to power the system. Asweep function generator 210 is used to generate a low frequency waveform for the audio function. Thesweep function generator 210 can generate an adjustable frequency of between about 1 Hz and about 1000 Hz. It can generate various types of waveforms, such as sweeping waveforms and ramping waveforms within that range of frequencies. Thesweep function generator 210 produces a sin wave signal that is transmitted to theaudio amplifier 230, which can be a 12V amplifier. Theamplifier 230 amplifies, the signal to about 50 W and transmits the amplified signal to the speaker oraudio transducer 870 connected to thevessel 800. Thesweep function generator 220 can be preset to a default frequency and waveform. In one embodiment, it can be preset to generate a 60 Hz signal, which can be manually altered to produce a signal at other frequencies between the range of about 1 Hz and about 1000 Hz. Anassembly control cable 240 connects the control box (not shown) with the electronic components of the system. The control box (not shown), which is housed underneath thecontrol panel lid 30, houses all of the circuit boards required to operate thesystem 10. - In one embodiment, as shown in
FIGS. 3A and 4B , on thebottom surface 61B of thelid 61 is acircular collar 300 that forms a perimeter around theopening 161 on thebottom surface 61B of thelid 61. An array ofUV LEDs 310 is mounted on the inner surface of the collar forming a ring. TheUV LEDs 310 each point toward the center of theopening 161. There can be as few as four LEDS and as many as one hundred twenty or more LEDs in the array ofUV LEDs 310. The array ofUV LEDs 310 can deliver 330 W of UVA at about 320 nm to about 400 nm. Alternatively, or in addition to, the array ofUV LEDs 310 can deliver 330 W of UVB at about 290 nm to about 320 nm. Alternatively, or in addition to, the array ofUV LEDs 310 can deliver 330 W of UVC at about 100 nm to about 200 nm. In one embodiment, there are ninety UV LEDs delivering 330 W of UVA at about 374 nm to about 392 nm, delivering a total of about 324 mW or 324 W. Thecollar 300 also includes amotion sensor 360 to detect when a limb has been inserted through the collar and the ring ofUV LEDs 310. The motion sensor is connected to the control box through awire 312 that is threaded through a bole in the collar and then a hole in the bottom of thecarriage 15 and up through the bottom of thecart 40. Thewire 312 is eventually bundled in thecable 240 and carries an electrical signal to the circuitry in the control box. The array ofUV LEDs 310 receives its electrical signals front the control box through awire 311 that is also threaded through the hole in the collar and then a hole in the bottom of thecarriage 15 and up through the bottom of thecart 40 and eventually bundled in thecable 240. - The
lid 61 is raised by lifting the distal side of the lid while the proximal side pivots along its hinges. Chains orwires 85 are connected at one of their ends to thebottom surface 61B of thelid 61 and at their other ends to the back panel of the cart with hooks or oilier securement means. Thelid 61 falls back and is supported by thechains 85. Thebottom surface 61B of thelid 61 includes agasket 184 around its square or rectangular perimeter that seals thebottom surface 61B of thelid 61 to thevessel 800 when thelid 61 is closed. - As shown in
FIG. 4A , thelid 61 can have a substantiallycircular crown 350 projecting vertically from itsupper surface 340. This crown is in lieu of thecollar 300 shown inFIGS. 3A and 4B . The array ofUV LEDs 310 is coupled to the inside surface of thecrown 350, as is themotion detector 360. The upper lid is formed bycovers covers portion portion circular wall covers portions circular crown 350 to form a substantial seal between the outer wall of thecrown 350 and the inner wall of the washer shaped raised portion. The outer wall of thecrown 350 can include a gasket (not shown) to reinforce the seal. The halfcircular walls opening 169 in the center that is concentric with and open to theopening 161 of thelid 61. - An
oxygen inlet port 77 on the washer shaped raised portion 62 (or alternatively on washer shaped raised portion 63) receives a hose (not shown) connected to an oxygen source, such as an oxygen lank or a central oxygen source in a hospital. Theoxygen inlet port 77 can include a fitting (not shown) to sealingly secure the hose to the cover raisedportion 62. The raisedportion 62 includes avapor inlet port 72 that receives the hose 70 (shown inFIG. 1 ). Thevapor inlet port 72 can include a fitting 73 (shown inFIG. 1 ) to sealingly secure thehose 70 to thevapor inlet port 72. - There are only two components of the
wound treatment system 10 that make physical contact with the patient's skin: a liner or bag 100 (as shown inFIGS. 3A and 4B ) into which the patient's limb is placed; and a foam cuff 90 (as shown inFIGS. 3B and 4A ), which is placed around the patient's limb. - The
liner 100 forms a treatment zone around the wound and makes contact with the open wound. Therefore, it is preferable that theliner 100 be biocompatible and sterile. Theliner 100 can be discarded or sterilized after each use and/or replaced with a new or sterilizedliner 100. - The material from which the
liner 100 is made can be any strong substantially gas impermeable material. Extruded flexible plastic film material, such as polyethylene (hdpe, ldpe, lldpe, polyprolene, etc.), polyurethane ether or ester open cell foam (e.g., United States Plastics Corp. Stock No. 47134), polyethylene terephthalate, polyvinyl chloride, or ethylene/polyvinyl copolymer sleet stock, and vapor proof treated fabric, such as nylon, are suitable. The material can be puncture resistant and transparent. The flexible sheet material can have a variety of shapes. It can be a single layer, such as a bag to surround a limb, or have multiple layers. The bag orliner 100 may also be co or tri axially oriented. - The term “substantially gas impermeable”, as used herein with respect to the sheet material, means gas impermeable to the extent needed to prevent excessive gas escape from the treatment zone through the sheet material. Total gas impermeability seldom is needed, particularly for continuous flow treatment devices. However, generally high impermeability is desirable for static treatment devices.
- The perimeter of the opening of the
liner 100 can have an adhesive strip with a removable backing. The backing can be removed und the perimeter of the lining can be substantially sealed against the crown 350 (or the collar 300), thus forming a scaled connection between the perimeter of the opening of theliner 100 and thelid 61. Alternatively, theliner 100 can be taped to the crown 350 (or the collar 300) to form a substantial seal between thelid 61 and theliner 100. - In one embodiment, the
liner 100 includes a pressure release valve 103 built into it. The design of thepressure release valve 105 is not critical. Many different types are suitable. For example, thevalve 105 can be a ball valve or a baffle valve such as a flap or butterfly baffle valve. Other valves are equally suitable, so long as they are capable of accurately setting the maximum release pressure and are inexpensive and so discardable. If desired theadjustable valve 105 can be calibrated to show the pressure setting. In one embodiment, the maximum release pressure can be set at 22 mm of mercury so that the pressure inside theliner 100 never surpasses that amount of pressure. The valve body can be made of any rigid plastic, although metals such as stainless steel can be used also. The spring can be steel or plastic. Very inexpensive completely plastic valves can be used as well. - The
pressure release valves 105 integrated with theliner 100 are inexpensive yet reliably accurate, within the preferred accuracy ranges. If desired, they can be removed from a usedliner 100 and reused on new liners. Using a valve that is in communication with the treatment zone and not with the gas supply eliminates the need for a separate pressure control mechanism between thechamber 810 and the oxygen source. Thechamber 810 can be connected directly to a gas or oxygen tank or a hospital gas supply line. - With any of the embodiments described herein, a
foam cuff 90, as shown inFIG. 3B , is placed around the patient's limb and inserted concentrically with the cylinder formed by the halfcircular walls foam cuff 90 can be disjoined so that it can be opened and placed around a limb. Thefoam cuff 90 can be made of a biocompatible open cell material that is compressible and resilient and forms a substantial seal or baffle between the patient's limb and the cylinder formed by thewalls foam cuff 90 as the pressure inside the treatment zone increases will prevent pressures from building up beyond that level. Thus, with the use of an open cell material in thefoam cuff 90, apressure release valve 105 in theliner 100 may not be necessary. Thefoam cuff 90 can also include a backing cm its outer non-skin contacting surface that can be peeled away, exposing a sticky surface that sticks to the cylinder. Thefoam cuff 90 can be made of a polyurethane ester or a natural material. -
FIGS. 5-7B show thevessel 800 in which the patient's wound is treated. Thevessel 800 sits inside of the rigidplastic carriage 15 shown inFIG. 1 . As shown inFIGS. 5 and 6A , thevessel 800 is formed by insertingchamber 810 intotank 830. The outer dimensions of thechamber 810 are slightly smaller than the inner dimensions of thetank 830 so that thechamber 810 is nested securely within thetank 830. The only dimension of thetank 830 that is substantially different from thechamber 810 is that thetank 830 is several inches deeper than thechamber 810. This provides for extra mom at the bottom of the lank 830 for the audio transducer orspeaker 870 connected to the bottom of thechamber 810, so that when thechamber 810 is placed in thetank 830, thetop edges chamber 810 andtank 830 are substantially coplanar as shown inFIG. 6A . - The
tank 830 is made of a molded plastic or metal that is rigid and durable. As shown inFIGS. 6A and 6B , thetank 830 has afoam platform 835 forming an inner bottom surface of thetank 830. Thefoam platform 835 has acircular pipe hole 836 cut into it that receives the audio transducer orspeaker 870. Thefoam platform 835 has asecond pipe hole 837 cut into it that is matched up with ahole 838 cut in the bottom of thetank 830 to form an outlet port for thewater pipe 818 projecting vertically downward from the bottom surface of thechamber 810.Bolts 833 projecting vertically downward from the bottom of thetank 830 are used to guide and connect thetank 830 to the carriage 13. - Turning to
FIGS. 7A and 7B ,chamber 810 is shown in more detail. Thechamber 810 includes a scalingmember 813 that surrounds the chamber just beneath itsedge 812. The sealingmember 813 forms a substantially fluid-tight seal between thechamber 810 and thetank 830. Inside the dumber 810 is anIR board 880 with an array of IR LEDs. Theboard 880 hasbolts 881 on its corners that are used to bolt theboard 880 to the bottom of thechamber 810.PCB wiring 881 is coupled to theIR board 880 and exits from thechamber 810 throughhole 882 drilled into the bottom of thechamber 810. Thehole 882 can be drilled at a location beneath theIR board 880 and can be about ¼ inch. Silicone, hot glue, and/or other sealing materials can be used to form a fluid tight seal between thewiring 881 and thehole 882 to seal thechamber 810, hardware, and wires front leaks. Thewiring 881 is lead through thepipe hole 837 in thetank 830 and connects with a connection to the control box. - The
IR board 880 includes IR LEDs arranged in a pattern on a square or rectangular board. The IR LEDs can emit energy at infrared frequencies of between about 700 nm and 30,000 nm. TheIR board 880 can be controlled by the control panel to adjust the frequency. In one embodiment, the IR LEDs deliver about 2000 mW of infrared light at about 810 nm. In one embodiment,tire IR board 880 can also generate about 1.2 W of Red light at about 660 nm for a combined total light output of 1911 mW. For example, theIR board 880 can be a Thor DDII IR Lamp System. - Turning to
FIG. 7A , a hole is drilled through the bottom of thechamber 810, and thewater pipe 818 is inserted through the hole, projecting vertically downward through the hole and out the bottom of thechamber 810. A tubseal pipe coupling 819 is used to form a fluid tight seal between thepipe 818 and the hole through which it is inserted through thechamber 810. Thewater pipe 818 is open at both ends to allow water to flow in and out of thechamber 810 when thechamber 810 is connected to thereservoir 600 through a water hose. - As shown in
FIGS. 7A and 7B , coupled to the outside of the chamber at the bottom of thechamber 810 is an audio transducer orspeaker 870. Thespeaker 870 is bolted to the bottom of thechamber 810.Transducer wires 876 are connected to thespeaker 870 and, like the IR wiring, are threaded through thepipe hole 837 in the lank 830 to form a connection with the control box. As shown inFIGS. 5 and 6A , a rigid plastic ormetal collar 890 with ahole 892 is placed around thespeaker 870 to protect thespeaker 870. Thespeaker 870 emits energy at a low frequency sound wave, of between about 1 Hz and about 1000 Hz. In one embodiment, the speaker emits energy at about 60 Hz. This causes a therapeutic vibration on thechamber 830 and a massaging effect on the patient's limb. - In one embodiment the
foam platform 835 is a premolded piece that is inserted into the bottom of thetank 810, and thechamber 810 is placed on top of thefoam 835. In another embodiment, a hardening foam gel is poured into the bottom of thetank 810 to a predetermined depth, and thechamber 810 withspeaker 870 andcollar 890 are quickly placed into thetank 810. The foam gel hardens around thepipe 838 andwires collar 890, and the bottom of thechamber 810. Thetank 830 is ultimately bolted to the rigidplastic carriage 15. - Now turning to
FIGS. 8A and 8B , the components of thewound treatment system 10 that are housed in thecan 40 are shown. BothFIGS. 8A and 8B are front views of thecart 40 looking at thecart 40 from the direction of viewing thecontrol panel 30.FIG. 8A shows the components with thehumidifier 400 removed so that thewater pump 500 is visible.FIG. 3B shows the components with the humidifier 4410 in its normal position blocking a view of thepump 500, which sits behind thehumidifier 400. - As shown in
FIG. 8A , awarm water reservoir 600 rests on ashelf 43 at the bottom of thecart 40. Afirst hose 510 is connected to thewater pump 500 throughlilting 512. The other end of thehose 510 is secured to a hose fitting 630 (shown inFIG. 9B ) laterally projecting from thereservoir 600 so that the hose is in fluid communication with the inside of thereservoir 600. Asecond hose 520 is connected to thewater pump 500 throughfitting 522. The oilier end ofhose 520 is connected to thewater pipe 818 projecting vertically from the bottom of thevessel 800 so that thehose 520 is in fluid communication with the inside of thechamber 810.Cables 510 electrically couple the water pump to the control box. Thereservoir 600 has arigid lid 610 dial can, be removed to expose the inside of the reservoir and fill it with water. - Turning to
FIGS. 9A and 9B , thereservoir 600 is shown in more detail. Thereservoir 600 includes twofloat switches upper float switch 640 is used to determine when thereservoir 600 is full and alower float switch 650 is used to determine when thereservoir 600 is empty.Switch 640 has a lead 642 that is electrically connected toterminal block 660 withwire 645.Switch 650 has a lead 652 that is electrically connected toterminal block 660 withwire 655.Terminal block 660 is electrically connected to the pump withwires 670. The spacing between theswitches chamber 830 when thesystem 10 is activated and the pump function is operating. Theswitches chamber 830. If too much water is pumped into the chamber, thelid 61 can dislodge causing thechamber 830 to leak. If there isn't enough water, the patients limb will not be warmed enough. In one embodiment, about five gallons of water is pumped from thereservoir 600 to thechamber 830. When the pump function is activated, the pump begins to pumpwater 500 out of thereservoir 600 throughfitting 660. When the water level reaches thelower switch 650 and the floatingarm 653 of theswitch 650 begins to dip fall, an electrical signal is transmitted to thepump 500 throughwires 670, and thepump 500 automatically shuts oil. When the drain function is activated, thepump 500 begins to pump in reverse, draining the water from thechamber 830 and back into thereservoir 600. When the water in the reservoir reaches theupper switch 650 and the floatingarm 643 of theswitch 640 begins to rise, an electrical signal is transmitted to thepump 500 throughwires 670, and the pump automatically turns off. - In one embodiment, the water is kept at an optimal temperature with a
portable healing unit 680 that is adjustable between a range of about 70.degree. F. and about 90.degree. F. In another embodiment, a more sophisticated heating unit is used (not shown) that is electrically coupled to the control box and can be controlled with a thermostat in thecontrol panel 30. - Turning back to
FIG. 8B , thehumidifier unit 400 sits atop thelid 610 of thereservoir 600. The humidifier has aremovable lid 410 dial can be removed to fill the reservoir of thehumidifier 400 with water and an antibacterial agent, such as ionic silver, hydrogen peroxide, bacitracin, betadine, or isopropyl alcohol. In one embodiment, adiabatically humidified 1% hydrogen peroxide/silver solution is used, but other FDA approved topical antibacterial, antibiotic, antiseptics and antimicrobial solutions and agents, such as those described above, may also be used. - The
humidifier 400 has a misting unit that constantly produces mist as long as the humidifier function on thecontrol panel 30 is activated. The misting unit can be an adiabatic temperature controlled humidifier or ultrasonic nebulizer. Thehumidifier 400 can generate room temperature mist or heated mist. It can include a built-in heater (not shown) with an on/off switch and an indicator light that shows that the heater is on and at operating temperature. Warm mist temperature in thebag 100 can teach between about 77.degree. F. and about 82.degree. F. as measured with a temperature gauge in the lid assembly. The humidity in thebag 100 can reach about 89% to about 91% as measured by a humidity gauge. The humidifier has a transducer that generates ultrasonic energy at about 40 kHz, to create an adiabatic/humid mist that creates a cloud. Ultrasonic energy from the misting unit is not transmitted to the limb, which is about two feet away from the misting unit. When thevalve control unit 50 is opened, the mist travels from thehumidifier 400 into theexit tube 410 and out through theexit port 420 where it enters thevalve control unit 50. From there the mist travels through thetube 70 and into the treatment zone formed by thebag 100 surrounding the patient's limb. - In another aspect of the present invention, the variable hyperoxia treatment apparatus as shown in
FIG. 10 , provides at least one treatment chamber for receiving a body part that separates the electronic components of the apparatus from the oxygen supply and concentrator. Many of the component parts of this apparatus are similar or identical to those discussed in previous embodiments and aspects. A majority of the electrical components of the apparatus are isolated from the oxygen source and the components that deliver oxygen to the treatment chamber and the patient. In particular, thewater fill port 975, themedicine fill port 970, theadiabatic humidifier 980, theultrasound device 982, thehumidifier control valve 984, thecontrol panel 962, thetemperature sensor 952, thepressure sensor 950, thehumidity sensor 986, thelid sensor 928, the electrical connections to the UV/IR LED arrays 924 are preferably on one side of the treatment chamber while theoxygen intake port 946,oxygen control valve 940,oxygen concentrator 942 andoxygen delivery ports 948 are on the other side of the treatment chamber. Alternatively, theoxygen intake port 946,oxygen control valve 940,oxygen concentrator 942 andoxygen delivery ports 948 may be securely housed in a separate chamber isolated from electronic components of the apparatus but not separated by the treatment chamber. - Multiple arrays of UV and
IR LEDs 942 that irradiate the surface of the body part are mounted to the chamber. There may be as few as five LEDS one mounted to illuminate the front, one for the back, one for the left side, one for the right side and one for the base of the body part. Alternatively, there may bearrays 942 of ten to several hundred positioned similarly to irradiate the entire body pan in the treatment chamber. The array ofUV LEDs 942 can deliver 330 W of UVA at about 320 nm to about 400 nm. Alternatively, or in addition to, the array ofUV LEDs 942 can deliver 330 W of UVB at about 290 nm to about 320 nm. Alternatively, or in addition to, the array ofUV LEDs 942 can deliver 330 W of UVC at about 100 nm to about 200 nm. In one embodiment, there are ninety UV LEDs delivering 330 W of UVA at about 374 nm to about 392 nm, delivering a total of about 324 mW or 324 W. - The IR board includes
IR LEDs 942 arranged in a pattern about the chamber. TheIR LEDs 942 can emit energy at infrared frequencies of between about 700 nm and 50,000 nm. TheIR LEDs 942 can be controlled by thecontrol panel 962 to adjust the frequency. In one embodiment, theIR LEDs 942 delivers about 2000 mW of infrared light at about 810 nm. In one embodiment, theIR LEDs 942 can also generate about 1.2 W of red light at about 660 nm fix a combined total light output of 1911 mW. For example, theIR LEDs 942 can be a Thor DDII IR Lamp System. The programmed treatment also sends electrical signals from the control box to the arrays of UV/IR LEDs 942 through a wire that is also threaded through die device and eventually bundled in the cable leading to thecontrol panel 962. - The lid is provided as a two-piece
circular collar 926 that forms a perimeter around the opening of the treatment chamber. Sliding apart the two pieces of thecircular collar 926 opens the lid. The lid also includes asensor 928 to detect the diameter of the body part that has been inserted through thecollar 926. Thesensor 928 wire is threaded through the device and eventually bundled in the cable leading to thecontrol panel 962. The diameter of the body part is relayed to a processor in thecontrol panel 962 that establishes the amount of humidified mist and oxygen that will be applied to the body part for each step of the programmed treatment. - An
oxygen inlet port 946 receives a hose (not shown) connected to an oxygen source, such as an oxygen lank or a central oxygen source in a hospital. Theoxygen inlet port 946 allows oxygen to flow from the source to anoxygen flow meter 944 in communication with theoxygen concentrator 942. Theoxygen concentrator 942 and/oroxygen flow meter 944 is in communication with theliner 900 through a one-way valve 940 allowing control of oxygen to tire treatment zone. Theoxygen concentrator 942 and/or oxygen flow meter is also in communication with a cannula or facemask that may be worn by the patient during treatment. The oxygen supply line hose may be sealingly affixed to aninlet port 946 on tire side of the apparatus (not shown) which is directly connected to theoxygen flow meter 944 and/oroxygen concentrator 942. - The
liner 900 forms a treatment zone around the wound and makes contact with the open wound. Therefore, it is preferable that theliner 900 be biocompatible and sterile. Theliner 900 can be discarded or sterilized after each use and/or replaced with a new or sterilizedliner 900. The material from which theliner 900 is made can be any strong substantially gas impermeable material. Extruded flexible plastic film material, such as polyethylene (hdpe, ldpe, lldpe, polyprolene, etc,), polyurethane ether or ester open cell foam (e.g., United States Plastics Gap. Stock No. 47154), polyethylene terephthalate, polyvinyl chloride, or ethylene/polyvinyl copolymer sheet stock, and vapor proof treated fabric, such as nylon, are suitable. The material can be puncture resistant and transparent. Theliner 900 also has at least two one-way inlet valves 940 at or about its base for receiving mist/medicated mist from thehumidifier 980 and oxygen from theoxygen flow meter 944 and/oroxygen concentrator 942. The design of the oneway valves 940 is not critical. A variety of different types may be utilized. Theliner 900 may also have an outlet port (not shown) that may be utilized for allowing replacement of agents in the treatment zone with fresh or other agents during the programmed treatment. - The perimeter of the opening of the
liner 900 can have an adhesive strip with a removable backing. The backing is removed and the perimeter of the lining substantially is sealed against the two-pieces of thecollar 926 tints terming a sealed connection between the perimeter of the opening of theliner 900 and the lid. Alternatively, theliner 900 may have a foam rim orcuff 916 about the opening with a drawstring,lire foam rim 916 provides a comfortable seal around the body part being treated when the drawstring is tightened. - The
liner 900 may also have apressure release valve 914. The design of thepressure release valve 914 is not critical. Many different types are suitable. For example,tire valve 914 can be a ball valve or a baffle valve such as a flap or butterfly baffle valve. Other valves are equally suitable, so long as they are capable of accurately setting the maximum release pressure. If desired the adjustable valve can be calibrated to show the pressure setting. In one embodiment, the maximum release pressure can be set at 22 mm Hg so that the pressure inside theliner 900 never surpasses that amount of pressure. The valve body is preferably made of any in expensive rigid plastic. - Coupled to the bottom of the chamber on its outside surface is an audio transducer or
speaker 960. Transducer wires are connected to the speaker and threaded through the apparatus to form a connection with thecontrol panel 962. A rigid plastic or metal collar with a hole is placed around thespeaker 960 to protect thespeaker 960 during use. Thespeaker 960 emits energy at a low frequency sound wave, of between about 1 Hz and about 1000 Hz. In one embodiment, thespeaker 960 emits energy at about 60 Hz. This causes a therapeutic vibration on the chamber and a massaging effect on the patient's body part. The components or the variable hyperoxia treatment apparatus are housed in a cart. Awarm water reservoir 995 is contained at the bottom of the cart. A first hose is connected to thewater pump 990 and the other end of the hose is secured and in fluid communication with the inside of the one or more chambers. A second hose (not shown) is connected to thewater pump 990 and the other end of hose can be connected to a waste container or drain. Cables electrically couple the water pump to the control box. Thereservoir 995 provides an opening that allows the reservoir to be filled with water. - The water may be kept at an optimal temperature with a portable heating unit (not shown) that is adjustable between a range of about 70° F. to about 90° F. Alternatively a (tearing unit within the apparatus may be used (not shown) that is electrically coupled to the
control panel 962 and can be controlled with a thermostat in thecontrol panel 962. - The
humidifier 980 is positioned above thewarm water reservoir 995. Thehumidifier 980 is in fluid communication with awater reservoir 975 that has a removable lid to enable filling with fluid and/or medication. Amedication reservoir 970 for receiving medications and/or medication dosage is in fluid communication with thehumidifier 980 so that it may be mixed with fluid to create an adiabatic vapor or mist for treatment. - The
humidifier 980 produces mist when the humidifier function on thecontrol panel 962 is activated. The misting unit can be an adiabatic temperature controlledhumidifier 980 orultrasonic nebulizer 982. Thehumidifier 980 can generate room temperature mist or heated mist, live humidifier may further comprise atemperature controller 954 with an on/off switch and an indicator light that shows when thetemperature controller 954 is on and at operating temperature. When thehumidifier control valve 984 to thehumidifier 980 is opened, the mist travels from thehumidifier 980 into the treatment zone through a one-way valve in theliner 900. Warm mist temperature in theliner 900 can reach between about 77° F. to about 82° F. as measured by a temperature sensor. The humidity in theliner 900 can reach about 89% to about 91% as measured by ahumidity sensor 986. Thehumidifier 980 has a transducer that generates ultrasonic energy in theultrasonic nebulizer 982 at about 40 kHz to create an adiabatic/humid mist. Ultrasonic energy from the misting unit is not transmitted to the limb. - In another embodiment, the
oxygen flow meter 944 andconcentrator 942 andhumidifier 980 are also in fluid communication with an outlet port that is influid communication 916 with a treatment chamber remote to the cart. Thetreatment chamber 910/914 (FIG. 11 ) comprises a pre-molded form adapted to encompass a non-limb body part such as a scalp, a thigh or the back. Thechamber 910/914 is composed of a semi-rigid polymer having a cushioned perimeter edge for sealingly engaging the body pan. Its configuration will depend on the area being treated. For example, a half domed shape may be desired for treating a particular location on the back while a helmet shaped dumber would be desirable for treating the scalp. The chamber may have at least two inlet ports, one for the humidified mist from thehumidifier 980 and one for oxygen from theoxygen flow meter 944 and/oroxygen concentrator 942. There may be an additional outlet port (not shown) to allow for replacing the existing agents in the chamber with new or other agents. Thetreatment clumber 910/914 may further comprise UV/IR USDs for illuminating the treatment area. The U V/IR LEDs are in electrical communication with thecontrol panel 962. This electrical communication line may be affixed to or integrated withintubing 912 and has a connector nearadapters 916 for connecting to the control pane) 962. A disposable orautoclavable liner 900 having at least two one-way ports at 940 and 984 for receiving humidified mist and oxygen lines the chamber. Theliner 900 may also have apressure release valve 914. The perimeter edge of theliner 900 may have adhesive for affixing theliner 900 to the rim of the chamber before use. - The disclosure set forth above is provided to give those of ordinary skill in the an a complete disclosure and description of how to make and use embodiments of the compositions and methods of the present invention, and are not intended to limit the scope of what the inventors regard as their invention. Modifications of the above-described modes (Tor carrying out the invention that are obvious to persons of skill in the art) are intended to be within the scope of the following claims. All publications, patents, and patent applications cited in this specification are incorporated herein by reference in their entirety as if each such publication, patent or patent application were specifically and individually indicated to be incorporated herein by reference.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/444,984 US20220072288A1 (en) | 2013-06-29 | 2021-08-12 | Medical treatment system and method of use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2013/048801 WO2014092802A1 (en) | 2012-12-10 | 2013-06-29 | Medical treatment system and method of use |
US201514648434A | 2015-05-29 | 2015-05-29 | |
US16/692,197 US11090475B2 (en) | 2013-06-29 | 2019-11-22 | Medical treatment system and method of use |
US17/444,984 US20220072288A1 (en) | 2013-06-29 | 2021-08-12 | Medical treatment system and method of use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/692,197 Continuation US11090475B2 (en) | 2013-06-29 | 2019-11-22 | Medical treatment system and method of use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220072288A1 true US20220072288A1 (en) | 2022-03-10 |
Family
ID=58463985
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/648,434 Active 2034-10-18 US10485963B2 (en) | 2013-06-29 | 2013-06-29 | Medical treatment system and method of use |
US16/692,197 Active 2033-09-26 US11090475B2 (en) | 2013-06-29 | 2019-11-22 | Medical treatment system and method of use |
US17/444,984 Pending US20220072288A1 (en) | 2013-06-29 | 2021-08-12 | Medical treatment system and method of use |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/648,434 Active 2034-10-18 US10485963B2 (en) | 2013-06-29 | 2013-06-29 | Medical treatment system and method of use |
US16/692,197 Active 2033-09-26 US11090475B2 (en) | 2013-06-29 | 2019-11-22 | Medical treatment system and method of use |
Country Status (4)
Country | Link |
---|---|
US (3) | US10485963B2 (en) |
EP (1) | EP3013407B1 (en) |
CA (1) | CA2894184C (en) |
WO (1) | WO2014092802A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3013407B1 (en) | 2013-06-29 | 2024-01-24 | Vaporox, Inc. | Medical treatment system |
WO2015142528A1 (en) * | 2014-03-19 | 2015-09-24 | Adrian Pelkus | Portable medical treatment system and method of use |
US10180248B2 (en) | 2015-09-02 | 2019-01-15 | ProPhotonix Limited | LED lamp with sensing capabilities |
CN213642639U (en) * | 2016-10-14 | 2021-07-09 | 蒸汽热能公司 | System for fluid circulation in a respiratory therapy unit and vapor transfer system |
US11207435B2 (en) * | 2018-01-31 | 2021-12-28 | Sensor Electronic Technology, Inc. | Humidifier disinfection using ultraviolet light |
US11504268B2 (en) * | 2018-06-27 | 2022-11-22 | Ethicon, Inc. | Wound treatment system |
CN109464272A (en) * | 2018-12-12 | 2019-03-15 | 江苏美德愈医疗科技有限公司 | The negative high voltage diabetes Wound treating device and operating method of segmented |
CN109464732A (en) * | 2018-12-12 | 2019-03-15 | 江苏美德愈医疗科技有限公司 | A kind of diabetes Wound treating device of multi-point injection high-pressure atomization medical fluid |
CN109529022A (en) * | 2019-01-05 | 2019-03-29 | 江苏美德愈医疗科技有限公司 | A kind of diabetic foot wound externally applied drug and its application method |
CN109718464A (en) * | 2019-01-05 | 2019-05-07 | 江苏美德愈医疗科技有限公司 | A kind of foot trauma therapeutic equipment |
CN111973437A (en) * | 2020-09-07 | 2020-11-24 | 中南大学湘雅医院 | Portable chronic wound surface hyperbaric oxygen therapeutic instrument |
AU2021378393A1 (en) | 2020-11-16 | 2023-07-06 | Vaporox, Inc. | Multistage vaporizer for medical treatment system |
CN113198093A (en) * | 2021-04-29 | 2021-08-03 | 潘晓峰 | Thoracic surgery medicine feeding device |
US20230043049A1 (en) * | 2021-08-09 | 2023-02-09 | Photonic Healing, LLC DBA Visum Light | Mobile configurable light therapy device |
CN113813486A (en) * | 2021-08-10 | 2021-12-21 | 天津怡和嘉业医疗科技有限公司 | Humidifier and ventilation treatment equipment |
IT202100024173A1 (en) * | 2021-09-21 | 2023-03-21 | Themis S R L S | SYSTEM FOR THE TREATMENT OF HEADACHES AND/OR SCALP THROUGH LED THERAPY, MAGNETICALLY ACTIVATED WATER AND MASSOTHERAPY PERFORMED WITH ELECTRONICLY CONTROLLED MECHANICAL DEVICES |
US11857799B2 (en) | 2022-01-07 | 2024-01-02 | Soletluna Holdings, Inc. | Wearable selective biophoton reflector |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100022941A1 (en) * | 2006-07-24 | 2010-01-28 | Adrian Pelkus | Wound treatment system and method of use |
US20110238004A1 (en) * | 2009-03-06 | 2011-09-29 | Bioquell Uk Limited | Improvements in or relating to wound treatment apparatus |
US20130019374A1 (en) * | 2011-01-04 | 2013-01-24 | Schwartz Alan N | Gel-based seals and fixation devices and associated systems and methods |
US8663179B2 (en) * | 2004-03-22 | 2014-03-04 | Cure Care, Inc. | Wound treatment system and method of use |
US9050448B2 (en) * | 2006-12-19 | 2015-06-09 | Cedars-Sinai Medical Center | Ultrasonic bath to increase tissue perfusion |
US9375586B2 (en) * | 2013-03-15 | 2016-06-28 | Pavel V. Efremkin | Apparatus and method for treatment of foot and nail diseases |
US11090475B2 (en) * | 2013-06-29 | 2021-08-17 | Vaporox, Inc. | Medical treatment system and method of use |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3101716A (en) | 1961-01-13 | 1963-08-27 | Jr Edward Shelton Cornell | Cabinet for treating limbs with radiation |
US3744491A (en) | 1972-01-20 | 1973-07-10 | B Fischer | Low pressure localized hyperbaric oxygen chamber |
US4236513A (en) | 1979-04-18 | 1980-12-02 | Lopiano Rocco W | Pulsed oxygen chamber |
JPS5775663A (en) | 1980-07-22 | 1982-05-12 | Kiichirou Sarui | Apparatus for treating dermatophytosis |
IT8421362V0 (en) | 1984-03-26 | 1984-03-26 | Dragone Giorgio | DEVICE FOR DERMATOLOGICAL TREATMENT OF HANDS. |
US4772259A (en) | 1987-06-12 | 1988-09-20 | Ballard Medical Products | Hyperbaric oxygenation apparatus and methods |
IT1230268B (en) | 1989-06-13 | 1991-10-18 | Todeschini Carlo Mandello Del | EQUIPMENT FOR THE EXECUTION OF GYNNASTIC EXERCISES IN A CONTROLLED ATMOSPHERE. |
US5228431A (en) * | 1990-04-26 | 1993-07-20 | Giarretto Ralph R | Drug-free method for treatment of the scalp for therapeutic purposes |
US5098415A (en) * | 1990-10-09 | 1992-03-24 | Jack Levin | Device and method for using an aqueous solution containing ozone to treat foot diseases |
US5312385A (en) | 1991-10-09 | 1994-05-17 | University Of Pittsburgh | Device for protected pulse irrigation |
US5447504A (en) | 1993-05-03 | 1995-09-05 | Baker; Gregg R. | Misting apparatus for the treatment of injured areas and method therefor |
US7771402B2 (en) | 1996-07-11 | 2010-08-10 | PulseCare Medical | Wound irrigation containment arrangement |
US5848998A (en) | 1996-07-11 | 1998-12-15 | Marasco, Jr.; Patrick V. | Tissue debriding apparatus |
RU2145247C1 (en) | 1998-04-10 | 2000-02-10 | Жаров Владимир Павлович | Photomatrix therapeutic device for treatment of extended pathologies |
US7744557B2 (en) * | 1998-05-19 | 2010-06-29 | Lexion Medical, Llc | Method and apparatus for delivering an agent to the abdomen |
US6936044B2 (en) * | 1998-11-30 | 2005-08-30 | Light Bioscience, Llc | Method and apparatus for the stimulation of hair growth |
US20080091179A1 (en) | 1999-12-10 | 2008-04-17 | Candela Corporation | Compact, handheld device for home-based acne treatment |
US6273906B1 (en) | 2000-02-02 | 2001-08-14 | Jean D. Swanson | Foot care device |
US7297211B2 (en) | 2003-05-09 | 2007-11-20 | Mystic Tan, Inc. | Single-dose spray system for application of liquids onto the human body |
US7014630B2 (en) | 2003-06-18 | 2006-03-21 | Oxyband Technologies, Inc. | Tissue dressing having gas reservoir |
US8353882B1 (en) | 2004-03-22 | 2013-01-15 | Iyia Technologies, Inc. | Wound treatment system and method of use |
CN1788709A (en) | 2004-12-16 | 2006-06-21 | 吴旭武 | Oxygen therapeutic method for promoting wound healing and related apparatus |
US7665460B2 (en) | 2005-10-11 | 2010-02-23 | Kimberly-Clark Worldwide, Inc. | Micro powered gas-forming device |
WO2007143715A2 (en) | 2006-06-07 | 2007-12-13 | Trinity Wound Institute, Llc | Oxygen therapy with ultrasound |
US8048044B2 (en) | 2007-08-14 | 2011-11-01 | Stryker Corporation | Drug delivery system |
US8287506B2 (en) | 2007-10-26 | 2012-10-16 | Electrochemical Oxygen Concepts, Inc. | Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability |
CN201171784Y (en) | 2008-01-20 | 2008-12-31 | 赵增友 | Human closed nested warm-pressing negative-ion medicine fog steam-bathing physiotherapy equipment |
US20090234270A1 (en) * | 2008-03-11 | 2009-09-17 | Ondine International, Ltd. | Therapy and device for treatment of nail infections |
US20100150991A1 (en) | 2008-12-15 | 2010-06-17 | Bernstein Brent H | Combination Wound Therapy |
US8758291B2 (en) | 2009-08-07 | 2014-06-24 | Acute Ideas, Inc. | Wound ventilation system |
EP2295963B1 (en) | 2009-09-11 | 2013-12-25 | MICROTEC S.r.l. | Method and apparatus for determining the knot-to-volume ratio of wooden planks |
AU2010320709B2 (en) * | 2009-11-18 | 2015-04-09 | Reckitt Benckiser Llc | Ultrasonic surface treatment device and method |
US8499764B2 (en) | 2010-05-26 | 2013-08-06 | The Invention Science Fund I, Llc | Portable apparatus for establishing an isolation field |
US20120022436A1 (en) | 2010-07-26 | 2012-01-26 | Sarasota Medical Products, Inc. | Disposable Environmental Control Chamber for Managing Wounds |
US8939152B2 (en) | 2010-09-30 | 2015-01-27 | Breathe Technologies, Inc. | Methods, systems and devices for humidifying a respiratory tract |
US9050208B2 (en) | 2011-05-27 | 2015-06-09 | Kci Licensing, Inc. | Systems and methods for delivering fluid to a wound therapy dressing |
-
2013
- 2013-06-29 EP EP13861708.9A patent/EP3013407B1/en active Active
- 2013-06-29 WO PCT/US2013/048801 patent/WO2014092802A1/en active Application Filing
- 2013-06-29 CA CA2894184A patent/CA2894184C/en active Active
- 2013-06-29 US US14/648,434 patent/US10485963B2/en active Active
-
2019
- 2019-11-22 US US16/692,197 patent/US11090475B2/en active Active
-
2021
- 2021-08-12 US US17/444,984 patent/US20220072288A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8663179B2 (en) * | 2004-03-22 | 2014-03-04 | Cure Care, Inc. | Wound treatment system and method of use |
US20100022941A1 (en) * | 2006-07-24 | 2010-01-28 | Adrian Pelkus | Wound treatment system and method of use |
US9050448B2 (en) * | 2006-12-19 | 2015-06-09 | Cedars-Sinai Medical Center | Ultrasonic bath to increase tissue perfusion |
US20110238004A1 (en) * | 2009-03-06 | 2011-09-29 | Bioquell Uk Limited | Improvements in or relating to wound treatment apparatus |
US20130019374A1 (en) * | 2011-01-04 | 2013-01-24 | Schwartz Alan N | Gel-based seals and fixation devices and associated systems and methods |
US9375586B2 (en) * | 2013-03-15 | 2016-06-28 | Pavel V. Efremkin | Apparatus and method for treatment of foot and nail diseases |
US11090475B2 (en) * | 2013-06-29 | 2021-08-17 | Vaporox, Inc. | Medical treatment system and method of use |
Also Published As
Publication number | Publication date |
---|---|
CA2894184A1 (en) | 2014-06-19 |
US10485963B2 (en) | 2019-11-26 |
US20150297877A1 (en) | 2015-10-22 |
EP3013407B1 (en) | 2024-01-24 |
WO2014092802A1 (en) | 2014-06-19 |
EP3013407A1 (en) | 2016-05-04 |
US20200197678A1 (en) | 2020-06-25 |
EP3013407A4 (en) | 2017-05-31 |
US11090475B2 (en) | 2021-08-17 |
CA2894184C (en) | 2020-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220072288A1 (en) | Medical treatment system and method of use | |
US8353882B1 (en) | Wound treatment system and method of use | |
US8241258B2 (en) | Wound treatment system and method of use | |
US8663179B2 (en) | Wound treatment system and method of use | |
US8048044B2 (en) | Drug delivery system | |
US20200360579A1 (en) | Wound care and infusion method and system utilizing a therapeutic agent | |
US8357130B2 (en) | Wound care apparatus | |
US5848998A (en) | Tissue debriding apparatus | |
US20070118096A1 (en) | Wound care system | |
US11744961B2 (en) | Portable medical treatment system and method of use | |
US6277052B1 (en) | Method and system for passively exercising selected portions of a human body | |
US6030318A (en) | Method and system for passively exercising selected portions of a human body | |
MX2007012508A (en) | An apparatus and method of body contouring and skin conditioning. | |
US20120065576A1 (en) | Drug delivery system | |
RU64067U1 (en) | CAPSULE FOR ISOLATED TREATMENT OF BODIES | |
US20100010591A1 (en) | Non-invasic therapeutic treatment device | |
RU100712U1 (en) | DEVELOPMENT OF SOFTWARE BARBOTAGE SANITATION | |
CN110812072A (en) | A nursing device for children's shank wound | |
CN1823698A (en) | Fumigation treatment instrument |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: VAPOROX, INC., COLORADO Free format text: CHANGE OF NAME;ASSIGNOR:WOUND CARE, INC.;REEL/FRAME:058906/0698 Effective date: 20190117 Owner name: CURE CARE, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PELKUS, ADRIAN;REEL/FRAME:058278/0306 Effective date: 20150527 Owner name: WOUND CARE, INC., DISTRICT OF COLUMBIA Free format text: COURT ORDER;ASSIGNOR:CURE CARE, INC.;REEL/FRAME:058599/0391 Effective date: 20160323 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |